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The effect of Hyperbaric Oxygen Therapy on osteoclast and osteoblast function  
Hadil W. Al-Hadi 
Abstract 
Bone remodelling, the process by which the skeleton adapts to environmental 
changes, is dependent on the actions of osteoclasts that resorb bone and osteoblasts 
which make new bone matrix.  Aberrant remodelling underpins bone loss in several 
debilitating skeletal diseases such as osteoporosis, metastatic breast cancer and multiple 
myeloma. Changes in remodelling activity can also arise as a consequence of 
therapeutic intervention for instance intravenous bisphosphonate treatment is associated 
with osteochemonecrosis of the jaw and localised osteoradionecrosis is a common side 
effect of radiotherapy.  Hyperbaric oxygen is often used as an adjunctive therapy in the 
treatment of these disorders. HBO involves the administration of 100% oxygen at 
atmospheric pressures greater than one in sealed chambers. 
The following studies aimed to evaluate the effect of HBO, hyperoxia, and pressure on 
RANKL-induced osteoclast differentiation and bone resorption from RAW264.7 and 
human peripheral blood mononuclear cells (PBMC), and osteoblast differentiation in 
vitro. The study also aimed to further examine the effect of HBO on ex vivo osteoclast 
formation from peripheral blood monocytes obtained from patients undergoing HBO. 
Daily exposure to HBO for ninety minutes significantly suppressed osteoclast 
differentiation and bone resorption in mouse and human monocytes in normoxic and 
hypoxic conditions in vitro. The suppressive action of HBO on osteoclast formation was 
associated with a significant reduction in HIF-1α and RANK mRNA expression and 
HBO also caused a significant reduction in NFATc1 and DC-STAMP expression. This 
study has for the first time shown that HBO is able to reduce the ability of precursors to 
form bone resorbing osteoclast.  
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HBO also suppressed the ability of peripheral blood monocytes to develop into 
RANKL-induced resorptive osteoclasts.  In an ex vivo culture system the suppressive 
effect of HBO was meditated by an action prior to activation of osteoclast 
differentiation by RANKL and must therefore be an inhibitory effect on the ability of 
precursors to differentiate along the osteoclastic lineage.  
HBO also accelerates the rate of osteoblast differentiation and augments early stages of 
mineralization and has a more pronounced effect than hyperoxia or pressure alone. 
HBO enhanced bone nodule formation and ALP activity in human osteoblasts. 
Furthermore HBO promoted the expression of type I collagen and Runx-2 in both 
normoxic and hypoxic conditions. HBO had a greater effect on these key markers of 
osteoblast differentiation than hyperoxia or pressure alone. 
This study suggests that HBO suppresses osteoclast activity and promotes osteoblastic 
bone formation, which may at least in part mediate its beneficial effects on necrotic 
bone.  This provides evidence supporting the use of HBO as an adjunctive therapy to 
prevent osteoclast formation in a range of skeletal disorders associated with low oxygen 
partial pressure.  The study also provides further support for the use of HBO in the 
treatment of skeletal disorders associated with excessive resorption such as 
osteomyelitis, and also provides a potential mechanism through which short term HBO 
may help fracture healing. 
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Chapter one: Bone formation, resorption 
and hyperbaric oxygen therapy  
  
 2 
 
1.1 Bone 
Bone is a connective tissue which consists of mineralized extracellular matrix and 
contains three types of cell, which are osteoblasts, osteocytes, osteoclasts and lining 
cells (Yang  and Damron, 2008). The organic phase of the skeleton consists primarily of 
type I collagen and small amounts of non-collagenous proteins (Hill and Orth, 1998), 
whereas the inorganic component consists of calcium and phosphorus in the form of 
hydroxyapatite crystals (Spector, 1994). In bone hydroxyapatite is an imperfect crystal 
of calcium phosphate salt (Ca10[PO4]6[OH]2) having substitutions by magnesium, 
sodium, strontium carbonate, citrate and fluoride. Crystals are needle shaped, white in 
colour and measure 100-350 nm (Kandaswamy et al., 2000). Hydroxyapatite plays an 
essential role in the ability of bones to resist mechanical loading. 
Bone provides internal support for the body, attachment sites for tendons and muscles, 
protects body organs and is the main store for calcium and phosphate in the body. It can 
be sub-divided into two main types, compact or cortical bone (Fig. 1.1), which forms 
the exterior surface and cancellous or trabecular bone which resides within the cortical 
cavity (Hill and Orth, 1998). The distribution of type I collagen in trabecular bone can 
vary; normally in the adult skeleton this is organised into concentric layers with fibres 
in the same orientation in individual layers; this is termed lamellar bone. The second 
type, woven bone, typically forms during pathological processes such as fracture repair 
or diseases associated with high rates of remodelling such as Paget’s. Woven bone is 
rapidly formed and there is little organisation of the collagen fibres. It is structurally less 
competent than lamellar bone and can provide a ‘patch’ at fracture sites which is 
subsequently remodelled to lamellar bone. 
Bone tissue is formed through two independent processes, intramembranous ossification 
and endochondral ossification (Karsenty, 1999). In the case of intramembranous 
ossification, osteoblasts differentiate directly from mesenchymal cells and form new 
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bone by a process of appositional growth without the formation of a cartilaginous 
template. During endochondral ossification bone develops through a sequential process 
where mesenchymal cells form chondrocytes which proliferate and differentiate to form 
a cartilaginous template which is subsequently remodeled and replaced by true bone 
(Chung et al., 1998). 
 
Figure 1.1 Structure of typical long bone. Based on 
http://medicaldictionary.thefreedictionary.com/bone+matrix 
1.2 Bone remodelling 
Bone remodelling is the temporally and spatially coupled cellular process that maintains 
skeletal integrity. It involves the resorption of bone by osteoclasts followed by the 
synthesis of new bone matrix by osteoblasts. The correct balance between osteoclastic 
bone resorption and osteoblastic bone formation is important in maintaining 
physiological bone homeostasis, and disruption of the relationship between these cells 
can lead to bone disease (Duplomb et al., 2007). There are five phases in bone 
remodelling: quiescence, activation, resorption, reversal and formation (see Fig. 1.2).  
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During quiescence the bone surface is inactive, but upon activation osteoclasts are 
recruited to the bone surface where they resorb bone forming a resorption pit.  During 
reversal, osteoblasts are recruited to the pit and synthesise new bone to replace the 
resorbed tissue during the formation phase (Hill and Orth, 1998).  Under normal 
conditions in adults there is little net loss of bone during each remodelling cycle 
ensuring that bone mass remains relatively constant (Eriksen, 1986).  Disruption of the 
remodelling cycle is a common occurrence leading to bone loss in many skeletal 
diseases such as osteoporosis, metastatic breast carcinoma and multiple myeloma (Fohr  
et al., 2003). 
The three cell types that contribute to bone remodelling form from different lineages, 
osteoblasts, which are derived from mesenchymal osteoprogenitors; osteocytes, which 
are osteoblasts that become entrapped within lacunae during bone formation; and 
multinuclear osteoclasts, which are derived from the fusion of mononuclear monocytic 
precursors present in the marrow and circulation (Ehrlich and Lanyon, 2002).  
Osteoblast and osteoclast formation are tightly regulated processes dependent on a 
range of systemic and local signalling factors (Kong et al., 1999, Yasuda et al., 1998). 
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Figure 1. 2 Bone Remodelling process. Based on Brandi (2009) 
 
 
1.3 Bone cells 
There are two bone cell lineages. The first, osteoclasts, resorb bone. The other is the 
osteoblast family, which consists of osteoblasts that form bone, osteocytes that help 
maintain bone and lining cells that cover the surface of the bone (Fig. 1.3). 
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Figure 1.3 The origin and fate of bone cells. Based on 
washington.edu/bonebio/bonAbout/bonecells.html. 
1.4 Osteocytes  
Osteocytes, the most common cell found in mature bone, are derived from osteoblasts 
and are located within the bone matrix (Tate et al., 2004). Manolagas proposed that 
matrix-producing osteoblasts can become osteocytes, lining cells or undergo 
programmed cell death (Manolagas, 2000). Osteocytes have long cytoplasmic 
extensions which cover a vast surface area allowing them to perform a multipurpose 
role in bone biology, including detection of changes in mechanical loading. These 
cellular projections are located in thin canaliculi in the mineralised matrix and allow 
osteocytes to form connections via gap-junctions with neighbouring cells and with the 
bone surface (Aarden et al., 1999). 
osteoblast 
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1.5 Osteoclasts  
Osteoclasts are derived from haematopoietic cells found within the bone marrow and 
peripheral blood (Fujikawa  et al., 1996). Osteoclasts are derived from myeloid 
progenitors that give rise to both the monocyte-macrophage lineage and the osteoclast 
lineage (Suda et al., 1999). During osteoclast differentiation preosteoclasts attach to the 
bone surface and multinuclear osteoclasts are formed by the fusion of these precursors 
under the regulation of a complex cell signalling network (Kim et al., 2005). The 
earliest differentiated haematopoietic precursor able to form osteoclasts is the 
granulocyte-macrophage colony forming unit (CFU-GM) (Knowles and Athanasou, 
2009). As detailed below, osteoclast formation is dependent on many locally produced 
cytokines and systemic regulators.  However, central to this are receptor activator of 
Nuclear Factor kappa B ligand (RANKL) and macrophage colony stimulating factor 
(M-CSF), which are both essential for the formation and fusion of multinucleated cells.  
RANKL is a member of the Tumour Necrosis Factor superfamily expressed by 
osteoblasts and stromal cells in response to resorptive stimuli, which binds to its 
receptor RANK on osteoclast precursors (Yavropoulou and Yovos, 2008, Jones et al., 
2002). RANKL is primarily expressed by osteoblasts but also expressed by activated T 
cells, fibroblasts and mammary tissue (Anderson et al., 1997). It also plays a pivotal 
role in the regulation of dendritic cell survival, lymphocyte development and lymph 
node organogenesis (Kong  et al., 1999). Cell to cell contact between osteoblast/stromal 
cells and pre-osteoclasts is essential for the activation of RANK, although soluble forms 
of RANKL have been identified (Khosla, 2001). 
RANK is expressed by a number of cells, monocytes/macrophages, fibroblasts, 
chondrocytes, osteoclasts and osteoblasts as well as B-cells and dendritic cells, and can 
be induced by IL-1, TNF-α, parathyroid hormone (PTH) and M-CSF (Hofbauer, 1999). 
The absence of RANK leads to an osteopetrotic phenotype due to the lack of osteoclast 
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for bone resorption (Kong  et al., 1999); osteopetrotic is a descriptive term that refers to 
a group of rare, heritable disorders of the skeleton characterized by increased bone 
density on radiographs (Stark and Savarirayan, 2009). The binding of RANKL to 
RANK initiates a complex network of intracellular signal transduction cascades that 
stimulate the expression of a number of osteoclastic genes (Boyle et al., 2003). This 
involves the induction of TNFR-associated proteins (TRAFs) to RANK which in turn 
active (Fig. 1.4) Extracellular signal-regular kinase, JNK (c-jun N-terminal kinases), 
NF-κ B, Nuclear Factor Activated T cells cytoplasmic 1, and Activator Protein-1 (Lee 
and Kim, 2003). In addition, TNF-α can also directly induce osteoclast formation and 
can have a synergistic effect with RANKL; it may also increase bone resorption by 
stimulating the expression of other pro-inflammatory cytokines (Kurokouchi et al., 
1998).  
1.5.1 Osteoclast formation  
Osteoclast formation is stimulated in response to falls in circulating Ca2+ concentrations, 
physical inactivity and during fracture repair.  Of these stimuli, serum [Ca2+] has the 
greatest daily influence on osteoclastogenesis; low [Ca2+] leads to the production of 
parathyroid hormone (PTH) from the parathyroid glands (Bronner and Farach-Carson, 
2003). PTH has diverse effects on osteoclasts; it stimulates bone resorption by 
increasing osteoclastogenesis and enhances the resorptive activity of individual mature 
osteoclasts.  This action is mediated via an effect on osteoblasts; osteoclasts lack PTH 
receptors and are indirectly regulated via the activation of osteoblastic PTH receptors, 
which then signal to osteoclast precursors to stimulate their differentiation, fusion and 
activation (Bronner and Farach-Carson, 2003). There are two main growth factors 
required for the formation of functional osteoclasts, Macrophage-Colony Stimulating 
Factor and RANKL, which are expressed by osteoblasts in response to resorptive 
stimuli such as PTH (Hofstetter et al., 2003).  M-CSF plays a critical role in the 
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proliferation, survival and activation of osteoclast precursors (Yavropoulou and Yovos, 
2008, Hirayama  et al., 2005) and is also necessary for the growth, differentiation, 
activation and survival of cells of the mononuclear system (Felix et al., 1994). M-CSF 
is secreted by a number of cells including osteoblasts, fibroblasts, monocytes and 
endothelial cells (Leizer et al., 1990, Weir et al., 1993) in response to IL-1 and TNF-α 
(Leizer et al, 1990). It is essential for the initial stage of osteoclast formation, survival 
and motility and binds to c-Fms, a dimeric receptor tyrosine kinase (Fuller et al., 1993, 
Lean et al., 2000). M-CSF induces the expression of RANK, the receptor for RANKL 
(Yasuda et al., 1998), and activates Mitf and c-Fos which are required for osteoclast 
differentiation (Kawaguchi and Noda, 2000). 
The RANKL/RANK interaction is modified by another factor produced by osteoblasts 
called osteoprotegerin (OPG), which is a soluble decoy receptor for RANKL (Kong  et 
al., 1999b).  OPG sequesters RANKL preventing it from binding to RANK, thus OPG 
suppresses bone resorption and preserves the balance between resorption and formation 
(Suda et al., 1999, Simonet et al., 1997). Through the differential production of 
RANKL/OPG in response to stimuli osteoblasts play a critical role in the differentiation 
of osteoclasts (Faccio et al., 2005). Disruption of this fine balance can lead to 
inappropriate levels of osteoclast formation and excessive bone loss. The binding of 
RANKL to RANK activates multiple intercellular signalling cascades that regulate the 
expression of osteoclastic genes such as cathepsin K, tartrate resistant acid phosphatase 
(TRAP) and the calcitonin receptor (Matsumoto  et al., 2004, Kim et al., 2008b). The 
initial signal is propagated by TNF receptor associated factors (TRAFs) which interact 
with several mitogen activated protein kinase (MAPK) pathways leading to the 
induction and activation of transcription factors including nuclear factor of activation T 
cell (NFATc1), NF-кB and AP-1 members. NFATc1 is a transcription factor identified 
in T-cells. Osteoclastogenesis can be induced in the absence of RANKL with 
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overexpression of NFATc1 (Takayanagi et al., 2002). NFATc1 activation is required 
for the transcription of osteoclast genes. NFATc1 can activate TRAP, osteoclast 
associated receptor (OSCAR), Dendritic specific Transmembrane Protein                       
(DC-STAMP), integrin β3, and cathepsin K (Shaulian and Karin, 2001).  In addition it 
promotes expression of its own gene, in a Ca2+ calcineurin dependent manner (Kim et 
al., 2005, Matsuo et al., 2004 ) and NFATc1 in many cases also co-operates with other 
transcription factors such as PU.1, MITF, and AP-1 to augment the transcription of 
genes (Takayanagi et al., 2002). Also osteoclast formation is dependent on the ability of 
TGF-β to enable receptor activator of NF-kB ligand (RANKL)-induced commitment of 
haematopoietic precursors to the osteoclastic lineage (Fox et al., 2003).  
Koga et al. describe a more complex model of osteoclastogenesis in which co-
stimulatory mechanisms play an important role in osteoclast development (Koga et al., 
2004). Co-stimulatory inputs from immunoreceptor tyrosine-based activation motifs 
(ITAM) such as osteoclast-associated receptor (OSCAR), Triggering receptor expressed 
on myeloid cells 2(TREM
 2), Fc-gamma receptor (FcRγ) and DNAX-activating protein 
of kDa (DAP12) (Kim et al., 2008a) regulate osteoclast formation and function 
(Humphrey et al., 2005). OSCAR is a member of the immunoglobulin-like surface 
receptor family and plays an important role as a co-stimulating receptor for osteoclast 
differentiation by activating NFATc1 via association with FcRγ (Merck et al., 2004). 
Nemeth et al. demonstrated that OSCAR is involved in the positive feedback circuit of 
the immunoreceptor-NFATc1 pathway by providing co-stimulatory signals required for 
RANKL mediated activation of calcium signalling (Nemeth et al., 2011). Also RANKL 
induces osteoclastogenesis by stimulating DC-STAMP internalization, which is 
necessary for mononuclear osteoclast fusion (Kukita et al., 2004). Bone marrow 
mononuclear cells derived from DC-STAMP deficient mice do not form multinuclear 
osteoclasts, but have comparable tartrate-resistant acid phosphatase (TRAP) activity in 
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vitro. Moreover, the expression of osteoclast markers and transcription factors required 
for osteoclast differentiation, including RANK, c-Fos, and NFATc1, was induced by M-
CSF and RANKL in DC-STAMP-deficient cells (Matsuo et al., 2004 ), so DC-STAMP 
efficiently induces the formation of multinuclear osteoclasts indicating that DC-STAMP 
is indispensable for cell-cell fusion of osteoclasts. Yagi et al revealed that DC-STAMP 
is essential for cell-cell fusion of not only osteoclasts but also of macrophage giant cells 
(Yagi et al., 2005).  
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Figure 1.4 The role of RANKL, RANK, and OPG in osteoclastogenesis. RANKL stimulates 
committed osteoclast precursors and mature osteoclasts via binding to its receptor RANK. 
RANKL exists in soluble and membrane bound forms. Decoy receptor OPG inhibits 
RANKL/RANK interactions and OPG appears to be the rate restrictive factor that regulates 
osteoclast activity and bone mass. Also OPG was found to bind to the apoptosis-inducing TNF-
family molecule tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This figure is 
based on Kong et al. (1999a). 
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1.5.2 Osteoclastic bone resorption 
Bone resorption is a complex process during which osteoclasts break down the organic 
and inorganic components of bone.  This requires the differentiation of osteoclasts from 
monocytic precursors, their functional polarisation, attachment to the bone surface, 
formation of a sealing zone, and the release of proteolytic enzymes and protons to form 
a resorption pit (Dresner-Pollak and Rosenblatt, 2004, Lakkakorpi and Vannanen 1995). 
Actively resorbing osteoclasts typically possess a highly involute area of membrane 
opposed to the bone surface termed the ruffled border; this is the resorptive organ of the 
cell possessing a large surface area for efficient exchange of resorptive factors 
(Schlesinger et al., 1997). The ruffled border is circled by the sealing zone which is rich 
in F-actin and cell adhesion molecules that attach the cell to the bone matrix.  
Osteoclasts express a range of heterodimeric integrins that enable them to interact with 
specific arginine-glycine-aspartic acid (RGD) containing proteins on the bone surface 
such as osteopontin (Hughes  et al., 1993, Nesbitt et al., 1993, Helfrich et al., 1992, 
Flores et al., 1992).  Highly expressed integrins include αvβ3, α2βv, αvβ5 and α2β1 which 
have a significant role in the initiation and maintenance of resorption.  In particular αvβ3 
integrin appears to play a particularly important role (Chambers et al., 1986), enabling 
adhesion and migration to areas where resorption is going to occur (Lakkakorpi and 
Vannanen, 1995). Integrins also maintain the integrity of the sealed zone between the 
ruffled border and bone surface, and defects in this can lead to poor resorptive capacity 
(Nakamura  et al., 1999). 
Breakdown of the inorganic component of bone matrix is dependent on the generation of 
an acidic environment (pH 4-4.5) within the sealed zone.  Acidification of the sealed 
zone is achieved by the action of vacuolar H+-ATPases and chloride channels located in 
the osteoclast ruffled membrane (Edwards et al., 2006), which extrude H+ and Cl- ions 
into the sealed zone forming HCl which solubilises hydroxyapatite (Vaananen and 
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Laitala-Leinonen, 2008). Protons are generated in the osteoclast cytoplasm by carbonic 
anhydrase II, which catalyses the hydration of CO2 to HCO3- and H+, and is abundantly 
expressed on the inner surface of the ruffled border (Fig. 1.5).  Cytoplasmic pH is 
maintained by the action of a chloride bicarbonate exchanger (Cl-: HCO3-) on the apical 
surface of the osteoclast, which maintains osteoclast functionality by preventing 
alkalisation (Rousselle and Heymann, 2002). Numerous cell signals influence acid 
secretion, but one of particular interest is intracellular calcium and the ubiquitous 
calcium-binding protein, calmodulin. The unique acid-dependent dissolution of calcium 
salts produces high local extracellular calcium (Silver et al., 1988). This is related to a 
separate osteoclastic calcium regulatory mechanism that includes a calmodulin-
dependent calcium ATPase (Bekker  and Gay, 1990), and factors effecting osteoclastic 
intercellular calcium activity like matrix attachment (Miyauchi et al., 1991).  
Several proteolytic enzymes are responsible for organic matrix turnover; these include 
the matrix metalloproteinase (MMP) family which are Ca and Zn-dependent 
endoproteinases (Blavier and Delaisse, 1995, Mannello et al., 2006).  MMPs play an 
important role in bone remodelling and osteoclast differentiation and can activate the 
phospholipase C pathway which regulates expression of the AP-1 transcription factors c-
Jun and c-fos (Ricky et al., 2005, Engsig et al., 2000). MMP-9 in particular is highly 
expressed in osteoclasts and has a major role in regulating these osteoclastic activities 
(Blavier and Delaisse, 1995). MMPs are thought to be necessary for the migration of 
precursor and immature osteoclasts to the bone surface (Inui et al., 1999). Bone 
remodelling and resorption is also dependent on the synthesis of the cysteine protease 
cathepsin K (CK), which is another osteoclastic enzyme secreted into the sealed zone 
which degrades type I collagen and other matrix proteins (Troen, 2004). CK expression 
is up-regulated by RANKL in human osteoclasts via TNF receptor-associated factor 6 
(TRAF6) which activates several osteoclastic transcription factors that interact with the 
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promoter region of CK (Bruce R, 2006, Troen, 2005). MMPs and CK are transported 
from the endoplasmic reticulum within lysosomes and then released into the resorption 
lacuna (Delaisse et al., 2003). In the case of CK this is as an active form following 
intracellular processing of the inactive zymogen at low pH by other proteases or by 
autocatalysis (Teitelbaum, 2007). CK is critical for the removal of the organic 
components of bone; humans lacking CK develop pycnodysostosis a rare genetic 
disorder that is characterised by osteopetrotic bone abnormalities (Motyckova and 
Fisher, 2002). CK knockout mice also develop osteopetrosis and display features 
characteristic of pycnodysostosis; osteoclasts isolated from these mice exhibit impaired 
bone resorption capacity and make few resorption pits (Gowen et al., 1999). 
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Figure 1.5 Diagram showing an osteoclast attached to bone tissue. Active bone resorption 
occurs in a sealed compartment between the ruffled border and the bone surface. The bone 
matrix experiense acidification and demineralisation initially. Later carbonic anhydrase II (CAII) 
produces protons in the cytoplasm. They are transported over the ruffled border into the 
resorption lacuna by an osteoclast-specific V-ATPase. Chloride Channel 7 (CLCN7) transports 
chloride ions from the cytoplasm into the resorption lacuna to equilibrate the charge of ions 
across the membrane. Posteriorly, the degradation of the organic matrix is done by several 
proteolytic enzymes including the cysteine proteinases, for example, cathepsin K (CTSK), and 
the matrix metalloproteinases. This diagram is based on Balemans et al. (2005).  
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1.6 Osteoblasts  
Osteoblasts are derived from mesenchymal stem cells and are responsible for the 
deposition and mineralization of bone matrix. The events during osteoblast 
differentiation are outlined in Fig. 1.6. Osteoblasts arise from common progenitors 
which can also form chondrocytes, muscle and adipocytes under the regulation of 
various hormones and local factors (Yamaguchi and Sugimoto, 2000). Osteoblast 
formation is a consecutive process that involves the development of immature 
osteoblast before mature cell formation. 
Osteoblasts can be characterised by several markers with important roles in bone matrix 
synthesis and mineralization. These include alkaline phosphatase (ALP) and type I 
collagen (Murshed et al., 2005). Osteoblasts also secrete further extracellular matrix 
proteins including osteocalcein (OCN), matrix Gla protein (MGP), bone sialoprotein 
(BSPs), osteonectin and osteopontin (OPN) (Young et al., 1992, Harada and Rodan, 
2003). 
Several transcription factors are crucial for skeletogenesis and osteoblast differentiation 
including RUNX2 and osterix (Nakashima et al., 2002). They target osteoblast-related 
genes such as OCN, BSP, OPN and collagen type I (Ducy, 2000). Osteoblasts express 
receptors for various hormones including PTH (Dempster et al., 1993), 1α,25-
dihydroxyvitamin D3[1α,25(OH)2D3] (Lain et al., 1999), oestrogen (Boyce et al., 1999) 
and corticosteroids. Osteoblast derived osteocalcin has also recently been shown to 
function as an endocrine regulator of metabolism. Fulzele et al indicated that insulin 
signalling in osteoblasts regulates glucose metabolism via OCN (Fulzele et al., 2010).  
OCN stimulates insulin release from pancreatic beta cells and at the same time directs 
fat cells to release the hormone adiponectin, which increases sensitivity to insulin (Lee 
et al., 2007). In addition osteoblasts play an important role in osteoclast differentiation 
via the release of RANKL (Katagiri and and Takahash, 2002). 
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1.6.1 Osteoblast differentiation  
Osteoblasts differentiate from pluripotent mesenchymal progenitor cells under the 
control of various transcription and growth factors (Katagiri and and Takahash, 2002). 
Mesenchymal stem cells differentiate into immature osteoblasts, which express bone 
matrix protein genes. Through the actions of Runx2, and osterix (osx), the immature 
osteoblasts, which express high levels of OPN, differentiate into mature osteoblasts, 
which express high levels of OCN (Karsenty and Wagner, 2002, Phan and Zheng, 2004). 
Finally mature osteoblasts are embedded in the bone matrix to become osteocytes (Liu  
et al., 2001). The expression of Runx and osx are themselves under the control of BMP, 
TGF beta and other systemic factors as shown in Fig. 1.6. 
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Figure 1.6 Mesenchymal stem cells differentiate into osteoblasts under Runx2 and osterix, 
Mesenchymal cells can also form adipocytes, myocytes, and chondrocytes under the control of 
transcription factors. Runx2 is a key regulator of osteoblast differentiation pathway, while 
osterix is downstream of Runx2 and is important for osteoblast maturation. This figure is based 
on Phan and Zheng (2004). 
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Osteoblast formation is regulated by several cytokines including bone morphogenetic 
proteins (BMPs), transforming growth factors (TGF), fibroblast growth factor (FGFs), 
Wnt, and hedgehog proteins (Hu et al., 2004) with members of the TGF family arguably 
being the most important of these (Cohen, 2002).  The TGF superfamily is comprised of 
over forty members such as TGF-β, activin and BMPs (Guo and Wang, 2009). BMPs 
are osteoinductive factors that stimulate ectopic cartilage and bone formation 
subcutaneously or intramuscularly in experimental animals (Rosen and Thies, 1992). 
BMPs regulate multiple processes such as proliferation, apoptosis, differentiation, cell-
fate determination and morphogenesis. BMPs are expressed in a wide range of tissues, 
for instance BMP3, BMP4 and BMP7 are expressed in the kidney; BMP2, BMP4, 
BMP5 and BMP7 in limb buds; and BMP2, BMP4 and BMP7 during tooth 
development (Chang et al., 1994).  Chen et al demonstrated that BMP2 exerts this 
osteogenic action by activating Smad (The mothers against decapentaplegic) signalling 
which regulates transcription of osteogenic genes (Chen et al., 1997). BMPs bind type 
II and type I serine/threonine kinase receptors, which activate specific Smad proteins 
(Itoh et al., 2000). BMPs induce canonical Smad1/5/8 phosphorylation in osteoblasts 
(Zhou et al., 2010, Fuentealba et al., 2007) and osteoblast-specific Smad1 knockout 
mice develop an osteopenic phenotype, whereas combined loss of Smads 1/5/8 results 
in severe chondrodysplasia (Wang et al., 2011, Retting et al., 2009).  BMP action is 
modified by a range of antagonists such as noggin and chordin which regulate BMP 
receptor binding. In the same way several lines of evidence indicate that Indian and 
sonic hedgehog modulate BMP function during pattern formation including skeletal 
formation in vertebrates (YamaguchiI et al., 2000).  Moreover FGF signalling was 
reported to modify BMP signalling and bone formation. FGF-2 and FGF-9 increase 
BMP-2 and TGF-β1 expression and endogenous FGF/FGFR signalling is a positive 
upstream regulator of the BMP-2 gene in calvarial osteoblasts (Fakhry et al., 2005), 
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potentially through the upregulation of Runx2 (Choi et al., 2005).  Furthermore, FGF-2 
and BMP-2 have a synergistic effect on fracture healing: FGF-2 has a critical function at 
early stages while BMP-2 promotes mineralization at later stages (Hughes-Fulford and 
Li, 2011). FGF-2 null mice have impaired nuclear accumulation of Runx2 and hindered 
BMP-2 induced bone formation and ALP activity (Naganawa et al., 2008).  
Wnt signalling also influences osteoblast proliferation, function and survival. Wnts are 
secreted, lipid-modified glycoproteins that activate cell surface receptor-mediated signal 
transduction pathways to regulate cell fate, proliferation, migration, polarity, and gene 
expression (Moon et al., 2002). Wnts activate at least three distinct intracellular 
signalling cascades: the Wnt-β-catenin pathway, the Wnt-Ca2+ pathways or the Wnt-
planar polarity pathway. The Wnt-β-catenin pathway is commonly referred to as the 
canonical pathway. It promotes cell fate determination, proliferation and survival by 
increasing β-catenin levels and altering gene expression through lymphoid enhancer 
factor-T cell enhancer factor (Lef-Tcf) transcription factors (Behrens et al., 1996).  In 
addition β-catenin, a factor that mediates the canonical WNT signalling pathway, also 
regulates low-density lipoprotein receptor-related protein 5 (LRP5), a WNT co-receptor 
that regulates bone formation (Mundy, 2002).  In addition to promoting osteoblast 
maturation Wnts play a role in lineage determination of mesenchymal precursor cells 
(Westendorf et al., 2004).  
1.6.2 Osteoblastic transcription factors  
Runx2 has been identified as a master transcription factor for skeletal formation and 
mineralisation by promoting early stages of osteoblast differentiation (Kern et al., 
2001). Runx expression is first detected in preosteoblasts, upregulated in immature 
osteoblasts but downregulated in mature osteoblasts. It triggers the expression of major 
bone matrix genes such as OCN, type I collagen and OPN (Ducy et al., 1997) during the 
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early stages of osteoblast differentiation but is not essential for the maintenance of these 
genes in mature osteoblasts (Komori, 2010). Runx2 is expressed exclusively in 
mineralized tissues and its expression precedes osteoblast differentiation and OCN 
expression by several days (Ducy et al., 1997). It promotes osteoblast maturation by 
supporting exit from the cell cycle and activating genes that facilitate osteoblast 
differentiation, indicating that Runx2 has a dual biological role in the osteogenic lineage 
attenuating proliferation and promoting maturation (Pratap et al., 2003). However, 
Runx2 expression in distinct proliferating mesenchymal cell types does not necessarily 
result in activation of mature bone phenotypic markers raising the question of whether 
Runx2 has a regulatory function in proliferating osteoblasts before osteoblast maturation 
(Stricker et al., 2002). 
Osteoblasts must synthesise collagenous extracellular matrix (ECM) before they will 
differentiate and express osteoblast-related genes such as OCN, BSP and ALP and 
ultimately mineralize (Franceschi, 1999).  This requires Runx2 to cooperate with 
several other transcription factors to enable its action on osteoblast differentiation.  
Some of these factors provide co-stimulatory signals while others repress Runx2 
activity by affecting DNA binding activity or transactivation potential. One of these is 
osx which is a zinc finger-containing transcription factor required for the differentiation 
of preosteoblasts into mature osteoblasts (Cao and Chen, 2005, Nakashima et al., 2002).  
Osx is expressed in osteoblasts of all endochondral and membranous bones and is 
necessary but not sufficient for hMSC osteoblast differentiation.  In the absence of osx, 
no cortical or trabecular bone forms through intramembranous or endochondral 
ossification. Osx acts downstream of Runx2 because osx null preosteoblasts express 
chondrocyte marker genes, suggesting that Runx2-expressing preosteoblasts are still bi-
potential (Nakashima et al., 2002). Osx regulates the expression of a set of ECM 
proteins, which are involved in terminal osteoblast differentiation (Zhou, 2011). Osx 
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was found to form a complex with NFAT, promoting osteoblastic bone formation 
through the activation of COLIA1 promoter activity (Koga et al., 2005). Osx expression 
is induced by a range of factors know to promote bone formation including BMP2 and 
BMP6 (Friedman et al., 2006). Matsubara et al found that Smad signaling is required 
for induction of osx and that expression is regulated by Runx2-dependent and 
independent mechanisms via BMP2 signaling (Matsubara et al., 2008). 
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Figure 1.7 This diagram shows the signal transduction pathways that regulate osteoblast 
function. Bone morphogenetic protein (BMP) binds to its receptor and induces the formation of 
a complex in which the type II BMP receptor phosphorylates and activates the type I BMP 
receptor. RUNX2 and osterix (two transcription factors that control osteogenesis) are 
upregulated by phosphorylation of the SMAD proteins. BMP2 was also shown to activate p38 
mitogen-activated protein kinase (MAPK), leading to an increase in RUNX2 transcription. In 
the same way, TGFβ regulates RUNX2 transcription by phosphorylating SMAD2 and SMAD3 
also by activating p38 MAPK. On the other hand, the WNT proteins interact with WNT 
receptor frizzled and co-receptor LRP5 or LRP6 to activate a signalling pathway that stabilizes 
cytoplasmic β-catenin. Diagram is based on Logothetis and Lin (2005). 
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1.7 Bone formation  
There are two types of bone formation, the first, intramembranous, occurs in parts of the 
flat bone of the skull and clavicle. Intramembranous formation beings with the 
condensation of mesenchymal cells which differentiate directly into osteoblasts that 
produce a mineralised extracellular matrix. The structure of the bony element formed is 
determined genetically and does not require mechanical inputs.  The second type of 
formation, endochondral ossification, occurs in long bones such as the femur.  During 
endochondral bone formation a cartilaginous template is generated by chondrocytes, this 
is subsequently replaced by true bone through the action of chondroclasts and 
osteoblasts (Mundy, 1999). 
The formation of bone by either endochondral or intramembranous ossification involves 
two principle steps, firstly, production of extracellular organic matrix (osteoid), then 
mineralization of the matrix to form bone. Osteoid is primarily composed of type I 
collagen fibres which give bone tensile strength and also provides a backbone for the 
deposition of bone mineral (Hollinger  et al., 2004). The production of type I collagen 
in itself may provide a stimulus for later events during bone formation. Previous studies 
demonstrated that osteosarcoma cells, calvarial osteoblasts and preosteoblasts show 
increased expression of ALP and other markers of the osteoblastic phenotype when 
plated on type I collagen (Aronow et al., 1990, Shi et al., 1996) and other studies have 
shown that ALP expression depends on type I collagen (Masi et al., 1992, Lynch et al., 
1995, Celic  et al., 1998). Furthermore, Lynch et al suggested that type I collagen was 
needed for the formation of mature osteoblast phenotype and mineralization of the 
extracellular matrix (Lynch et al., 1995) and showed abnormal expression and synthesis 
of type I collagen in subchondral osteoblasts coupled with low mineralization, which 
mimics the in vivo situation. 
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Non-collagenous proteins also play a key role in regulating the nucleation and 
maturation of mineral as well as the activity, localisation and differentiation of bone 
cells. These proteins are primarily secreted by osteoblasts during formation and include 
OPN, ON and OCN as well as cytokines such as TGF-β (Nefussi et al., 1997).  OPN is 
the primary protein induced by cellular transformation and it is produced at late stages of 
osteoblastic maturation during matrix formation. In osteoclasts it has been shown to 
induce intracellular signalling pathways (Sodek et al., 2000). ON, an acidic 
glycoprotein, plays an essential role as a regulator of bone remodelling. It is essential for 
the maintenance of bone mass and for balancing bone formation and resorption.  ON 
also promotes osteoblast differentiation and cell survival (Kapinas et al., 2009). OCN is 
an extracellular matrix protein produced by osteoblasts; it has a role in the early stages 
of bone healing and has been shown to stimulate adhesion of osteoblast-like cells 
(Ingram  et al., 1993).  It was first discovered as a calcium binding protein which can 
undergo vitamin K dependent γ-carboxylation. The γ-carboxylated form binds 
hydroxyapatite and is abundant in bone extracellular matrix. OCN is expressed by 
osteoblasts, odontoblasts, and hypertrophic chondrocytes at the onset of tissue 
mineralization and accumulates in the bone extracellular matrix (Hauschka and Wians, 
2005).  OCN avidly binds hydroxyapatite via 3-carboxylated glutamic acid residues and 
was originally thought to play a role as a regulator of mineral nucleation (Shanahan et 
al., 2000). However, Lain et al implicated OCN as a potential inhibitor of bone 
formation and a role for OCN in bone resorption is strongly supported by a series of in 
vivo and in vitro studies relating OCN in bone to osteoclast recruitment and activity 
(Lain et al., 1984). Therefore, OCN can no longer be considered a passive marker of 
mineralization.  OCN deficiency has long been associated with increased bone formation 
(Price, 1989). Young et al suggested that osteocalcin expression is restricted to growing 
bone implicating its role in the modulation of mineralization (Young et al., 1992). Ducy 
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et al indicated that OCN deficient transgenic mice have increased bone formation 
without impairing bone resorption or affecting mineral content, suggesting OCN 
prevents excessive bone formation (Ducy et al., 1996). 
Bone formation involves the proliferation of primitive mesenchymal cells, their 
differentiation into osteoblast precursors (osteoprogenitor, pre-osteoblast), formation of 
mature osteoblasts, formation of matrix and finally mineralization. Osteoblasts converge 
at the bottom of the resorption cavity and form osteoid which begins to mineralize until 
the cavity is filled (Hill and Orth, 1998). During mineralisation matrix vesicles are 
exocytosed from osteoblasts into sites where calcification will occur. Mineral crystals 
then begin to form within the vesicles which are augmented by ALP and 
pyrophosphatase and calcium binding proteins such as annexin I. The next phase of the 
process is when the crystals are released from the vesicles exposing them to the 
extracellular fluid. This contains high concentrations of Ca2+ and PO4 allowing the 
crystals to act as nuclei around which further crystals can develop by homologous 
nucleation. Mineralisation is further controlled by interactions with the inorganic 
components of the matrix which act as initiators or inhibitors of nucleation thereby 
assuring that crystal growth is spatially and temporally appropriate (Balcerzak, 2003). 
Mineralisation is assisted by the release of osteoblastic ALP. In both bone and calcifying 
cartilage ALP is expressed early in development and is soon observed on the cell surface 
and in matrix vesicles. The principal regulatory pathways controlling ALP expression is 
the BMP/RUNX2/ osterix system and the WNT signalling cascade, which also interact 
with each other (Gaur et al., 2005). Gong et al demonstrated that a number of Wnt 
proteins are capable of inducing ALP in mesenchymal cells (Gong et al., 2001).  Rawadi 
et al shows that Wnt/LRP5 controls the expression of ALP through the canonical β-
catenin cascade and that the capacity of BMP-2 and Shh to induce the expression of 
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ALP in mesenchymal cells is dependent on the integrity of this pathway (Rawadi et al., 
2003). 
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1.8 Hyperbaric Oxygen Therapy 
Hyperbaric oxygen therapy (HBO) is the breathing of pure oxygen in a sealed chamber 
that has been pressurised at 1.5 to 3 times normal atmospheric pressure (London et al., 
1993). This differs from normobaric oxygen therapy (NBO), where raised oxygen levels 
are administered at one atmosphere (Singhal et al., 2005). The use of NBO as a simple 
first aid tool for decompression sickness has been advocated for a long time (Balestra et 
al., 2004) but is less effective than HBO (Beynon et al., 2007). The use of HBO as a 
medical therapy has a long history; in 1662 Henshaw, a British clergyman, first 
suggested that a rise in the ambient pressure around a patient may have therapeutic 
benefits, since this time, reports of beneficial effects from increased pressure have 
increased (Kindwall, 2002). Subsequently in 1877 a French surgeon called Fontaine 
developed the first mobile hyperbaric operating room, and at this time hyperbaric 
chambers were available in all large European cities. In the early 1900s Dr Orville 
Cunningham, a professor of anaesthesia at the University of Kansas, constructed the 
largest hyperbaric chamber in the world and used hyperbaric oxygen to treat various 
altered health states (Jain 2004). Modern clinical use of hyperbaric oxygen began in 
1955 with Churchhill-Davis who helped to attenuate the effects of radiation treatment in 
cancer patients using high oxygen environments.  
There are two types of hyperbaric chamber design. The first type is multiplace chambers 
that allow two or more people to be treated simultaneously. Multiplace chambers are 
usually metallic and are always pressurized with air, 100% oxygen being delivered to 
patients via an oronasal mask, head tent or endotracheal tube.  The second type is 
monoplace chambers, which are designed to treat a single patient and are pressurized 
with oxygen (Grim  et al., 1990). 
HBO can be employed as an intervention in a number of different disorders where body 
tissues have suffered from a decrease in oxygen levels leading to hypoxia due to a range 
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of causative factors (Kindwall, 2002, Albert 2008). These include decompression illness, 
severe carbon monoxide poisoning, smoke inhalation, treatment of chronic wounds and 
some infections, wound healing after reconstructive surgery, radiation necrosis, acute 
blood loss where a blood transfusion is not possible, relief of symptoms in multiple 
sclerosis, sports injuries, diabetic foot ulcer and refractory osteomyelitis.  HBO has also 
been used as an adjuvant therapy for the treatment of skeletal disorders such as 
osteonecrosis of the jaw, osteomyelitis and complicated fractures (Bartlett, 2000, 
Bennett et al., 2005). While positive effects of HBO on patient outcomes have been 
noted the cellular and molecular mechanism through which HBO may affect 
remodelling is poorly understood. 
1.8.1 Mechanisms of action  
HBO increases oxygen transfer to tissues by two mechanisms, first increasing the 
saturation of haemoglobin and secondly and potentially more importantly increasing the 
concentration of oxygen dissolved in plasma. Hyperbaric oxygen therapy increases the 
haemoglobin saturation with oxygen from 97% to 100%. HBO also increases plasma 
oxygen saturation (London et al., 1993).  Arterial oxygen tension is raised six fold when 
breathing 100% oxygen at 1 ATA, 14 fold under 2 ATA and 22 fold when under 3 ATA. 
Tissue oxygen tension rises to a maximum of 500 mmHg at 3 ATA, and increases the 
oxygen delivery up to 60 ml per litre of blood. This is enough to meet the basic 
metabolic tissue needs of reparative tissues in the human body without the contribution 
of haemoglobin (Tibbles and Edelsberg 1996, Evans, 2002). Normoxia, the 
concentration necessary to maintain aerobic metabolism and homeostasis in the body, is 
around 15%–21% O2. Oxygen tensions outside this normal range are defined as follows: 
anoxic (less than 0.01% O2), hypoxia (12% O2 or less), hyperoxia (45%–100% O2), and 
hyperbaric oxygen (any O2 tension greater than 1 atmosphere absolute pressure or 760 
mm Hg) (Widiyanti, 2011). 
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1.8.2 Evidence supporting the use of HBO in osteonecrosis and osteomyelitis  
HBO has been used to improve healing and restoration from infection in the patients 
(Zamboni et al., 2003). HBO increases oxygen transfer to tissues by two mechanisms, 
first increasing the saturation of haemoglobin and secondly and potentially more 
importantly increasing the oxygen concentration dissolved in plasma (London et al., 
1993). The efficacy of HBO in altered health states is attributed to a range of actions 
including the reversal of hypoxia, changes in vascular reactivity, reduced oedema, 
modulation of nitric oxide and reactive oxygen species production, modification of 
growth factor and cytokine production and modulation of the immune response (Wang 
et al., 1995). Refractory osteomyelitis is considered a form of chronic osteomyelitis that 
has reoccurred after appropriate intervention; HBO has been proved effective in the 
treatment of osteomyelitis promoting the repair and removal of necrotic bone (Davis et 
al., 1986).  In animal studies, HBO has been shown to improve both bone generation 
(Inoue et al., 2000) and the removal of dead or abnormal bone (Jones et al., 1991). HBO 
is often utilised in the treatment of chronic necrotizing infections of the skin usually as a 
consequence of a traumatic or surgical wound.  The increase in tissue oxygen levels 
after HBO enhances leukocyte mediated killing of bacteria and inhibits the growth of 
anaerobic organisms reviewed by (Tibbles and Edelsberg 1996). 
Osteonecrosis (ON) is the death of tissue due to hypoxia which has occurred as a 
consequence of trauma, surgery or chemo or radio therapy.  Osteoradionecrosis (ORN) 
is relatively common in individuals who have undergone radiotherapy of the head and 
neck to remove a tumour and osteochemonecrosis (OCN) is increasingly seen in 
individuals who have received anti-resorptive bisphosphonates to treat bony metastases 
(Vanderpuye and Goldson 2000). This primarily affects alveolar bone of the jaw due to 
its higher remodelling rate and as a consequence oxygen requirement in comparison to 
other systemic bone sites.  The incidence of this disorder varies considerably depending 
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on many factors such as treatment regime, dental health and follow-up time (Hansen et 
al., 2006, Wahl, 2006).  
The pathogenesis of ORN and in particular bisphosphonate-induced osteonecrosis 
(BRONJ) is not completely understood, but in the case of ORN is thought to occur when 
exposure to radiation damages blood vessels and osteocytes within the bone matrix 
leading to reduced vascularity and bone marrow fibrosis (Khoo, 2003).  Hypovascularity 
generates hypoxia within these regions, which in turn reduces the total number of bone 
cells at these sites and thereby disrupts the remodelling process (Maier et al., 2000).  
Marx described in 2003 the positive relationship between osteonecrosis and the use of 
bisphosphonates (Marx, 2003, Marx et al., 2005). Bisphosphonates are used to prevent 
resorption and skeletal disease in patients with osteoporosis, Paget’s disease and skeletal 
metastases.   
HBO stimulates monocyte and fibroblast function and collagen synthesis and increases 
vascular density (Annane et al., 2004). HBO is effective for the treatment of BRONJ, it 
increases local concentrations of reactive nitrogen species (RNS) and reactive oxygen 
species (ROS), which influence osteoclast differentiation and activity and regulate other 
critical aspects of bone metabolism. ROS enhance the expression of RANKL (Bai et al., 
2005), changing the RANKL/osteoprotegrin ratio and favouring osteoclast 
differentiation (Khosla, 2001). HBO generated ROS and RNS also induce stem cell 
mobilization and vasculogenesis; these effects help reduce the area of poorly 
vascularised bone and promote remodelling of necrotic areas.  
Osteomyelitis is a chronic or acute infection of bone which may remain dormant for 
many years (Gill and Bell, 2004). It is caused by bacterial or fungal infections and is 
associated with a pronounced osteolytic response.  HBO has been used to treat chronic 
refractory osteomyelitis since 1965 (Cierny et al., 1985) and can play an important role 
in the management of osteomyelitis (Mader et al., 1999). HBO therapy increases tissue 
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oxygen tension and promotes bone and soft tissue healing in ischemic tissue (Esterhai et 
al., 1987). HBO increases the oxygen concentration in infected tissue which inhibits the 
growth of anaerobic organisms and enhances the influx of immune cells (Mader et al., 
1989). The increase in oxygen tension also increases oxygen-dependent killing 
mechanisms of polymorphonuclear leukocytes. Hyperbaric oxygen therapy is effective 
and safe for chronic refractory osteomyelitis provided that patients have received 
appropriate medical and surgical management; this treatment modality remains 
encouraging for chronic osteomyelitis because of the high rate of wound complications 
and recurrence in this disease (Chen et al., 2003).  
1.8.3 Effect of HBO, oxygen and pressure on bone cells  
Oxygen availability plays a significant role in the regulation of bone cells. Hypoxia 
occurs when the blood supply to tissues is reduced or disrupted. Oxygen tension (pO2) 
in arterial blood is about 95mmHg (12%), and in venous and capillary blood it is about 
40mm Hg (5%), approximately a quarter of that in atmospheric air (Lewis et al., 1999). 
When the blood supply is reduced or disrupted oxygen levels fall and hypoxia can occur. 
The normal oxygen tension within bone tissue remains unknown. Lack of oxygen can 
result in a failure to generate sufficient ATP to maintain essential cellular functions, 
whereas excess oxygen (hyperoxia) results in the generation of damaging reactive 
oxygen intermediates.  
Changes in oxygen tension have a rapid and opposing effect on osteoblast and 
osteoclast activity.  Hypoxia stimulates osteoclast formation, resulting in resorption of 
significant amounts of bone (Arnett et al., 2003). Hypoxia enhances osteoclast 
differentiation through a direct effect on monocytic precursors (Zhao et al., 2011). 
Hypoxia has also been shown to reduce levels of IL-10, an inhibitor of osteoclast 
differentiation (Naldini et al., 1997). Exposure to hypoxia for longer than 24 hours or 
continuous HIF-1α expression is associated with a loss of membrane integrity and 
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reduced osteoclast number (Knowles and Athanasou, 2009). Utting et al (2006) 
demonstrated that hypoxia inhibits the proliferation of mature osteoblast precursors and 
leads to the failure of cell differentiation and formation in vitro (Utting et al., 2006). 
Also the exposure of mesenchymal stromal cell transplanted in vivo to hypoxia may 
affect their bone forming potential (Potier et al., 2007). Bone nodule formation was 
inhibited by hypoxia at both early and late stages (Utting et al., 2006). 
In contrast previous studies indicate that HBO has a positive effect on osteoblast 
differentiation, promoting ALP expression, bone nodule formation and mineralisation in 
vitro (Wu et al., 2007). HBO enhances bone accruement during experimental tooth 
movement and mandible distraction (Muhonen et al., 2004, Gokce et al., 2008) and 
promotes osteoblast proliferation and reduces apoptosis in-vivo (Wong et al., 2008). 
Ishii et al (1999) reported that intermittent HBO enhances collagen synthesis and is 
beneficial for producing extracellular matrices in tissue engineering (Ishii et al., 1999).  
Previous studies demonstrated that HBO decreased tissue damage and induced 
osteodentine formation in the rat mandible after vertical osteotomy (Nilson et al., 1987).  
Freiberger 2009 demonstrated that adjunctive HBO may benefit patients with 
bisphosphonate associated osteonecrosis of the jaw. This may be due to changes in the 
distribution of mononuclear cells (Bitterman et al., 1993, Freiberger, 2009). 
Recent studies have shown that oxygen tension regulates the formation and 
differentiation of various bone cells, including chondrocytes, osteoblasts and osteocytes 
(Hirao et al., 2006). Furthermore, while the effect of HBO on osteoclastogenesis has 
until now been poorly documented the importance of oxygen in osteoclast 
differentiation is more widely appreciated.  Yamasaki et al (2009) demonstrated that a 
high oxygen tension promotes the survival of human osteoclast precursors via up-
regulation of M-CSF (Yamasaki et al., 2009).  
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Another force acting on cells residing in the bone tissue is pressure. Cells in bone and 
connective tissue are also sensitive to variations in pressure. Rubin et al (1997) 
demonstrated that pressure is known to generate responses from bone cells and that 
continuous hydrostatic pressure at physiological levels decreased osteoclast formation 
in marrow cultures (Rubin et al., 1997). The effect of continuous static pressure on the 
differentiation of osteoblast was examined and it found that differentiation was inhibited 
as were collagen synthesis and ALP activity (Ozawa et al., 1990). Further, subtle 
changes in pressure accelerate the mineralization front in fetal bone rudiments (Burger 
et al., 1991). 
1.8.4 Cellular mechanisms for sensing changes in oxygen 
The level of hypoxia inducible factor (HIF-1α), a transcription factor responsible for the 
activation of hypoxia responsive genes, is rapidly modified by changes in oxygen 
concentration.  Under normoxic conditions HIF-1α and the closely related HIF-2α, are 
the targets of a family of prolyl-hydroxylases, which utilize molecular oxygen and 2-
oxoglutarate to selectively hydroxylate two conserved proline residues on the HIF-1α 
molecule (Epstein et al., 2001). These hydroxylated residues are then targeted by the 
ubiquitin ligase von Hippel-Lindau protein (pVHL), which polyubiquinates HIF 
targeting it to the proteasome for proteolytic destruction.  During hypoxia hydroxylation 
of HIF is inhibited allowing it to accumulate when prolyl hydroxylase domain (PHDs) 
are inhibited due to the lack of O2. This allows the accumulation of HIF heterodimers 
that drive the expression of oxygen sensitive genes (Maxwell et al., 1999). HIF-1α then 
diffuses into the nucleus, where it forms a complex with the HIF-1β subunit and recruits 
transcriptional co-activators such as p300/CBP for full transcriptional activity (Fig. 1.8). 
This binds to HIF responsive elements in the promoter region of a wide range of target 
genes required for the cellular adaptation to oxidative stress and induces their 
transcription. These target genes include genes involved in angiogenesis such as 
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vascular endothelial growth factor (VEGF), erythropoiesis, glucose metabolism, 
apoptosis, cell proliferation and survival, pH regulation and proteolysis                 
(Carroll and Ashcroft, 2005 ).  
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Figure 1.8 HIF-1α regulations by proline hydroxylation. In normoxic conditions HIF-1α is 
hydroxylated, polyubiquitinated, recognised by the proteasome and subsequently degraded. In 
hypoxic conditions proline hydroxylation is inhibited and thus HIF-1α is stabilised and 
accumulates. It translocate to the nucleus where it forms a complex and initiates transcription of 
oxygen responsive genes.  This figure is based on Ke and Costa (2006) and Hoeben et al. (2004). 
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1.9 Aims and objectives 
While it is clear that HBO has skeletal effects, the cellular and molecular mechanisms 
mediating this action are not well understood. Importantly the effect of HBO on 
osteoclastogenesis in human cells has not been studied.  Similarly the mechanisms by 
which human osteoclasts sense changes in O2 have not been ascertained.  Thus, to 
increase our knowledge relating to HBO and bone remodelling the current study aimed 
to try to understand the effect of HBO on osteoclast formation and bone resorption, and 
osteoblast formation to assess if one mechanism through which HBO helps skeletal 
healing is by an inhibition of osteoclastogenesis and stimulation of osteoblast 
differentiation. 
Objectives: 
1- to determine the molecular action of HBO on osteoclast differentiation, to 
evaluate the effects of HBO, hyperoxia and elevated pressure on RANKL-
induced osteoclast differentiation and bone resorption using RAW264.7 and 
human peripheral blood mononuclear cells (PBMC); 
2- to examine the effect of HBO on ex vivo osteoclast formation from peripheral 
blood monocytes obtained from patients undergoing HBO; and 
3- to evaluate the direct effect of HBO on osteoblast differentiation and bone 
nodule formation, and also to examine the effect of HBO, pressure and 
hyperoxia on proliferation, expression of key regulators and markers of 
osteoblast differentiation, and mineralised nodule formation such as Runx-2 and 
type I collagen; compared to normoxic and hypoxic conditions.  
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Hypotheses: 
HBO will suppress osteoclast formation from circulating monocyte, and increase 
osteoblast differentiation. 
HBO will suppress the expression of key genes required for osteoclast formation and 
increase genes required for osteoblast formation. 
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Chapter two: General materials and methods 
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2. Materials and methods 
2.1 Media and reagents 
Recombinant mouse RANKL, human RANKL and human M-CSF were purchased from 
Insight Biotechnology (Insight Biotechnology, Wembley, and London, UK). 
Ampicillin, streptomycin, DMEM, α-MEM culture medium and trypsin were obtained 
from Sigma Aldrich (Poole, Dorset, UK). All plastics, flasks and tubes were purchased 
from Fisher Scientific (Nunc, UK). The Cell Titer 96 AQueous non-reactive cell 
proliferation assay kit was purchased from Promega (Promega, Madison, USA). 
Antibodies were obtained from Abcam (Cambridge, UK). Hyperbaric oxygen chambers 
were obtained from the Diving Diseases Research Centre (DDRC), Plymouth, UK.  
Cylinders containing custom mixtures of O2, CO2 and N2 were purchased from DDRC.  
2.2 Cell culture 
Monocytic RAW264.7 cells were purchased from LGC standards (Teddington, London, 
UK) and human osteogenic sarcoma cells (Saos-2) were purchased from the European 
Collection of Cell Culture (ECCAC, UK). All experiments were performed in culture 
medium supplemented with 10% charcoal stripped fetal calf serum (Autogen Bioclear, 
UK), 2 mmol/l glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin all from 
Sigma Aldrich (Poole, Dorset, UK). Unless otherwise stated, incubations were 
performed at 37 °C in a humidified 5% CO2 incubator. Cultures were fed every 2-3 days 
by replacing half of the medium with fresh medium and cytokines. 
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2.3 Cryopreservation of cells 
Cells were cryopreserved and then used for experiments as required. Subconfluent cells 
were removed from culture vessels using trypsin-EDTA; 0.5% trypsin containing 0.5 
mM EDTA, at a dilution of 1:5, was added for 5 min at 37 °C with gentle agitation to 
help the cells detach. Following this, 5 ml of medium was added, and the mixture was 
centrifuged at 130 ×g for 5 min and resuspended in a solution of (v/v) 90% serum and 
10% DMSO. Cells were then stored at -80 °C in cryovials. 
2.4 Isolation and culture of peripheral blood monocytes 
Peripheral blood was obtained from healthy volunteers by venipuncture, using heparin 
to prevent coagulation in accordance with approved ethical guidelines. The blood was 
collected by a research nurse at the DDRC.  Blood was diluted 1:1 in un-supplemented 
media (α-MEM). Mononuclear cells were isolated by centrifuging 15 ml of αMEM 
blood suspension over 25 ml of Histopaque-1077 (Sigma-Aldrich, UK), at 700 ×g for 
30 min at 4 °C.  The buffy layer containing monocytes was removed and washed in 10 
ml of non-supplemented α-MEM then centrifuged at 400 ×g for 10 min at 4 °C (Fig. 
2.1).  The cell pellet was resuspended in culture medium containing 10% FCS and red 
cells lysed using a 10% acetic acid solution. Peripheral Blood Monocyte cells (PBMC) 
were counted in the resulting suspension using a haemocytometer. 
For the induction of osteoclast formation, 1 × 104 PBMCs were cultured in 96 well 
plates containing α-MEM supplemented with 50 ng/ml M-CSF and 30 ng/ml RANKL.  
For the assessment of bone resorption slices of devitalised cortical bovine bone were 
placed into the wells prior to the addition of cells.  Normoxic experiments were 
performed by incubating plates at 37 °C in a humidified atmosphere of 5% CO2 when 
cultures were not receiving experimental treatments. During hypoxic experiments plates 
were incubated in humidified air-tight chambers prepared at the DDRC at a temperature 
of 37 °C, which were flushed on a daily basis after experimental treatments with a gas 
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mixture consisting of 2% O2, 93% N2 and 5% CO2.  All cultures were fed every two-
three days by replacing half the medium with fresh medium and cytokines.  
Experiments were stopped after twelve days to assess osteoclast differentiation by 
staining for tartrate-resistant acid phosphatase (TRAP) and twenty days for bone 
resorption. 
 
 
Figure 2.1 Schematic view of monocyte separation. Samples layering before and after 
Histopaque-1077 density gradient centrifugation. This figure is based from 
www.biocompare.com. 
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2.5 Assessment of osteoclast differentiation  
Osteoclast formation was assessed by staining for the specific osteoclastic marker 
tartrate resistant acid phosphatase (TRAP), which was performed using an acid 
leukocyte (TRAP) kit (Sigma, Poole, Dorset, UK). Prior to staining cells were fixed 
with 10% formaldehyde/PBS for 10 min and then washed with distilled water. Cultures 
were then TRAP stained for one hour in a humidified chamber at 37 °C using naphthol 
AS-BI phosphate as a substrate and fast garnet GBS base as a chromogen. After 
washing in distilled water the number of TRAP-positive multinucleated cells (>3 nuclei 
per cell) and TRAP-positive mononucleated cells were scored at five predetermined 
sites of each well using an inverted light microscope (Olympus, Japan) fitted with an 
eyepiece graticule at with a ×40 objective. The number of TRAP positive cells per cm2 
was then calculated and a mean ± SEM recorded for each group. 
2.6 Assessment of bone resorption  
For the assessment of bone resorption cells were cultured on slices of devitalised 
cortical bovine bone. Bone slices were prepared from frozen sections of bovine femur 
obtained from an abattoir (Ashburton, Devon) using a low speed diamond saw (Buehler, 
Coventry, UK). 
Slices were then cleaned by ultrasonication in distilled water for 15 min and washed 
with acetone for 10 min. Slices were then sterilized in ethanol at room temperature and 
stored dry at -20 °C until used. After appropriate incubation times cells were removed 
from the surface of the bone slice by immersion in sodium hypochlorite for five 
minutes, washed in distilled water for five minutes and stained with 1% toluidine blue 
solution for ten minutes. Slices were then air-dried and mounted on glass slides using 
double sided tape.  Resorption pits appeared as darkly stained, clearly marginated areas 
using reflected light microscopy and resorption area was quantified across the entire 
 45 
 
surface of the slice using an eye-piece graticule with a ×40 objective.  Resorption was 
then calculated as the percentage of bone surface displaying pits. 
2.7 Measurement of proliferation  
Cell proliferation was measured using the Cell Titer 96 AQeous non-reactive cell 
proliferation kit. This uses mitochondrial NADH/NADPH-dependent dehydrogenase 
activity as a marker of cell proliferation, which converts a substrate (3-(4,5-
dimethylthiazol-2-gl)-5-(3-carboxymethoxylphenyl)-2-(4-sulfhophenyl-2H) tetrazolium 
compound (MTS) into a soluble formazan.  Measurement of the absorbance of the 
formazan in experimental wells and wells with known cell numbers enabled the 
quantification of the number of viable cells.   
The assay was performed by discarding 20 µl of culture medium from each well and 
adding 20 µl of MTS solution.  Plates were then incubated at 37 °C for one hour and 
then absorbance was measured at 490 nm using a 96 well plate reader (Molecular 
Devices, USA). The viable cell number in each well was calculated by using A490 of the 
known standards and the equation of the line y = mx + c. 
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2.8 Measurement of mineralization and alkaline phosphatase activity  
Mineralization was assessed using a modification of Hale’s methodology (Hale et al., 
2000) by measuring calcein incorporation. Saos2 human osteoblast-like cells were 
cultured in 96 well plates (5 × 104 per well) and treated with β-GB (10 mM) and L-AA 
(50 mg/l). Culture medium was removed, and cells were washed with PBS and 
incubated in culture medium containing 1 mg/ml calcein for four hours at 37 ºC. 
Fluorescence was measured with a Cytofluor II fluorescence multi-well plate reader 
(Preseptive Biosystems, USA) at 485 nm excitation and 530 nm emission. 
ALP activity was measured by staining cultures with p-nitrophenyl phosphate (1 mg/ml) 
at 37 °C for 30 min. Absorbance was measured at 405 nm and the results were then 
normalized to total cell number. 
2.9 Molecular biology 
2.9.1 RNA Extraction 
Total RNA was isolated from cultures using a Sigma Genelute on-column RNA 
isolation kit. Cells were washed with PBS and RNA was extracted according to the 
manufacturer’s protocol. Genomic DNA was removed with an On-column DNase-I 
treatment step. The purity and concentration of RNA was measured using a Nanodrop 
spectrophotometer (ND-1000) (Labtech, UK). To assess the resolution of samples, 
absorbance was measured at 260 nm and 280 nm, and anA260/A280 ratio of 2.0-2.23was 
considered satisfactory).  All reagents and the consumables were RNase and DNase 
free. 
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2.9.2 Reverse transcription 
RNA (1 µg) was reversed transcribed to cDNA using the ImPromII Reverse 
Transcription System (Promega, Southampton, UK). The initial reaction consisted of 1 
µg of RNA and 0.5 µM random nonamers, in a final volume of 5 µl. This was incubated 
at 70 °C for 5 min and then quickly chilled on ice for 5 min. The reverse transcription 
reaction mix was then prepared by combining the following in a thin wall PCR tube on 
ice: nuclease-free water (to a final volume of 15 µl); ImProm-II™ 5× Reaction Buffer, 
4.0 µl; MgCl2 (final concentration 1.5-8.0 mM), 1.5 µl; dNTP mix (final concentration 
0.5 mM for each dNTP); recombinant RNasin inhibitor, 1.0 µl; and ImProm-II™ 
Reverse Transcriptase, 1.0 µl.  Tubes were then placed in a GeneAmp PCR System 
9700 machine and cycled under the following conditions; 10 min at room temperature 
followed by 37 °C for 50 min and 94 °C for 5 min. cDNAs were then stored at 4 °C 
until used. 
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2.9.3 PCR 
The primers were designed using the NCBI website’s primer Blast software, and 
purchased from Eurofins MWG Operons (Germany). 
Each PCR reaction contained 2 µl of cDNA; 2.5 µl of 10× buffer; 0.5 µl of forward and 
reverse primer (10 µM); dNTPs (0.5 mM); and 0.2 µl Taq DNA polymerase made to a 
final volume of 25 µl in RNAse free water. Reaction conditions were 94 oC for 2 min 
followed by 40 cycles at 94 °C for 30 s, 60 °C for 30 sand 72 °C for 30 s. 
Product size was confirmed using agarose gel electrophoresis. PCR samples had 2.5 µl 
of loading buffer (orange G and 10% glycerol) added before being loaded onto a 2% 
TAE agarose gel. Gels were made by dissolving agarose in an adequate volume of TAE 
buffer (Invitrogen, UK) which was heated in a microwave for 2-3 min, then cooled to 
50 °C before being set in a gel tray with appropriate sized well combs. A 1 kb DNA 
ladder was used (0.5 µg/lane). For the visualization of DNA under UV light, 1 µl of 
ethidium bromide (10 mg/ml) was added before gels were poured. Gels were run at 70-
100 V for 30 min and band size and presence checked using a UV gel documentation 
system (UViTech, Japan) linked to a PC (Toshiba, Japan). 
2.9.4 Quantitative RT-PCR 
Quantitative RT-PCR (qPCR) was used to detect the expression levels of key regulators 
of osteoclast and osteoblast differentiation using the ∆∆CT methodology.  Cells were 
plated in six well plates at an appropriate density and incubated for an appropriate time 
with a complete change of medium every three to four days.  Total RNA was then 
isolated using a Sigma Genelute RNA isolation kit and used in a revere transcription 
reaction to produce cDNA as detailed in Section 2.9.2. Real time PCR was performed 
on a StepOne PCR system linked to Step One v.2 software (Applied Biosystems,UK) 
using the DNA-binding dye SYBR green for detection of PCR products. β-actin was 
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used as a house keeping gene to normalise mRNA levels. A total of 2 µl of cDNA was 
added to a final reaction volume of 25 µl containing 0.05 U/µl Taq, SYBR green, PCR 
buffer (300 nM ROX reference dye) and specific primers (0.2 µM).  Reaction 
conditions were 94 °C for two min, followed by forty cycles of 94 °C for 30 s, 60 °C for 
30 s and 72 °C for 30 s.  PCR amplification was measured by fluorescence emitted from 
SYBR Green during the extension phase.  Gene expression was normalized to β-actin 
and expressed relative to the reference control group.  
 
2.10 In vitro exposure of cells to
 
HBO, altered pressure and oxygen conditions
 
For in vitro treatment of cells with HBO (97.9% O2, 2.4 ATA), elevated pressure (2.4 
ATA, 8.8% O2, 2.1% CO2, and 89.1% N2) and hyperoxic conditions (95% O2), cells 
were incubated in air-tight stainless steel chambers prepared at the DDRC (Fig. 2.2).  
Chambers were flushed for 4 min with relevant gas mixes and then pressurised to 2.4 
atmosphere absolute (ATA) over 2 min.  Cultures were exposed to HBO or pressure for 
ninety minutes to replicate the duration of treatment received by hyperbaric therapy 
patients; pressure chambers were decompressed over 8-10 min. 
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Figure 2.2 Miniature hyperbaric oxygen chambers. These enable high pressure 2.4 ATA and 
controlled oxygen exposure for cell research. 
 
 
2.11 Exposure of cells to normoxia (21% O2), hypoxia (2% O2), and hyperoxia 
(95% O2) 
For hypoxia (2% O2) normoxia (21% O2) and hyperoxia (95% O2) treatments cells were 
incubated in special air tight chambers prepared in Plymouth Hyperbaric Medical 
Centre in a total volume of five litres. Cells were also flushed with a gas mixture 
containing a 95% O2, 5% CO2 or 5% O2, 5% CO2 (balance N2) for 2-4 min at a rate of 4 
l min-1 in gas-tight plastic boxes (21.5 cm × 21.5 cm × 11 cm). This achieved the correct 
concentration inside the chamber box, based on direct measurement with an air flow 
meter (PCE-007, Dwyer Instruments Ltd High Wycombe, UK). Chambers were re-
gassed daily as above with appropriate O2 concentrations (Fig. 2.3). 
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Figure 2.3 Oxygen cylinders and boxes used in the experiments to provide normoxia, hypoxia 
and hyperoxia. 
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2.12 Statistical Analysis 
Statistical analysis was performed using one way ANOVA for comparison between 
groups.  All results are expressed as mean ± S.E.M. and significance was considered at 
P < 0.05. The analysis was performed using Statview statistical software (Abacus 
Concepts, California, USA). 
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Chapter three: The effect of hyperbaric oxygen therapy on 
osteoclast formation and bone resorption in vitro 
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3.1 Introduction  
HBO is the breathing of pure oxygen in a sealed chamber pressurised to greater than 
normal atmospheric pressure (Grim et al., 1990).  HBO is widely used as a treatment for 
decompression sickness and severe carbon monoxide poisoning, and is also used as an 
adjunctive treatment in non-healing diabetic wounds and necrotic skeletal disorders 
such as ORN and BRONJ.  HBO induces a tenfold increase in tissue oxygen tension 
primarily by elevating plasma oxygen (Tibbles and Edelsberg, 1996) and this enables a 
rapid delivery of oxygen to areas of ischaemic tissue damage as this is erythrocyte 
independent.  The subsequent transient increase in oxygen tension is thought to promote 
tissue regeneration through multiple mechanisms including changes in vascular 
reactivity and angiogenesis, reduced oedema, modulation of free radical production, 
bactericidal effects and modification of cytokine production and the immune response 
(Gill and Bell, 2004). 
Bone cells are acutely sensitive to changes in oxygen level and hypoxia is a hallmark of 
many skeletal disorders associated with aberrant levels of osteoclast activity (Hiraga et 
al., 2007, Kurowska-Stolarska et al., 2009).  In contrast, elevated oxygen levels promote 
M-CSF expression and osteoclast precursor survival (Yamasaki et al., 2009).  In healthy 
bone oxygen levels range from 6-9% but this falls to 1-3% at fracture sites and within 
necrotic bone (Maurer et al., 2006).  Unsurprisingly in light of the association between 
low oxygen level and pathological bone loss, hypoxia has been shown to augment 
osteoclast differentiation and bone resorption in vitro.  Arnetts et al.’s (2003) studies in 
mouse models indicate that hypoxia enhances osteoclast formation (Arnett et al., 2003) 
with similar results reported by other investigators (Muzylak et al., 2006, Srinivasan 
and Avadhani, 2007, Knowles and Athanasou, 2008, Utting et al., 2010).  Cells, 
including osteoclasts, sense changes in oxygen tension via the oxygen-dependent 
degradation of hypoxia-inducible transcription factors (HIFs) (Knowles and Athanasou, 
 55 
 
2008, Majmundar et al., 2010, Utting et al., 2010).  In normoxic conditions HIF-1α is 
rapidly hydroxylated by HIF prolyl hydroxylases (PHD).  Hydroxylation allows the 
ubiquitin kinase von Hippel-Lindau protein (pVHL) to bind HIF-1α and target it for 
proteasomal degradation.  Low oxygen levels limit PHD activity which enables an 
accumulation of HIF that drives expression of genes associated with the cellular 
response to low oxygen tension (Trebec-Reynolds et al., 2010). 
The augmentative effect of hypoxia on osteoclast formation is blunted by transient 
exposure to elevated oxygen in vitro (Knowles and Athanasou, 2009).  However at 
present there is little information regarding the effect of HBO on osteoclast 
differentiation and activity and it is unclear if HBO is more effective than elevated 
oxygen or pressure alone (Gray and Hamblen, 1976).  Similarly the molecular action of 
HBO on osteoclast differentiation has also to be determined.  To address these questions 
the current study evaluated the effects of HBO, hyperoxia and elevated pressure on 
RANKL-induced osteoclast differentiation and bone resorption from RAW264.7 and 
human peripheral blood mononuclear cells (PBMC). 
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3.2 Experimental design 
 
Figure 3.1 Experimental design. Monocytes, obtained from healthy volunteers, and RAW264.7 
cells were treated with RANKL and M-CSF, then incubated in normoxic conditions (21% O2, 1 
ATA) or normoxic conditions, with ninety minutes per day exposure to HBO (97.9% O2 at 2.4 
ATA), hyperoxia (95% O2, 1ATA) or elevated pressure (8.8% O2, 2.4 ATA). For RAW 264.7 
cells, experiments were stopped after four days to assess osteoclast differentiation, after eight 
days for resorption. For hPBMC experiments were stopped after twelve days to assess 
osteoclast differentiation and after twenty days for resorption. 
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3.2.1 RAW264.7 osteoclast formation assay 
RAW 264.7 cells were cultured under standard conditions prior to the start of 
experiments (5% CO2 in a humidified environment at 37 °C) in DMEM supplemented 
with 10% fetal calf serum, 100 mg/ml streptomycin, 100 mg/ml penicillin and 100 
mg/ml L-glutamine (Invitrogen, Oxford, UK).  For the induction of osteoclast formation 
cells were cultured at 5 × 104 cells/well in 96-well plates and treated with RANKL (30 
ng/ml). For the assessment of bone resorption cells were cultured on slices of 
devitalised bovine cortical bone.  Normoxic experiments were performed by incubating 
plates at 37 °C in a humidified atmosphere of 5% CO2 when cultures were not receiving 
experimental treatments. During hypoxic experiments plates were incubated in 
humidified airtight chambers prepared by the DDRC at a temperature of 37 °C, which 
were flushed on a daily basis after experimental treatments with a gas mixture 
consisting of 2% O2, 93% N2 and 5% CO2.  All cultures were fed every two-three days 
by replacing half the medium with fresh medium and cytokines.  Experiments were 
stopped after four days to assess osteoclast differentiation and eight days for resorption 
(Fig. 3.1). 
3.2.2 Isolation and culture of peripheral blood monocytes 
Peripheral blood was obtained from healthy volunteers by venipuncture using heparin to 
prevent coagulation in accordance with approved ethical guidelines, as described in 
Chapter 2, Section 2.4 (Fig. 3.1). 
3.2.3 Exposure of cells to normoxia (21% O2), hypoxia (2% O2) and hyperoxia 
(95% O2) 
For hypoxia (2% O2), normoxia (21% O2) and hyperoxia (95% O2) treatments cells 
were incubated in airtight chambers, as described in Chapter 2, Section 2.11. 
 58 
 
3.2.4 Exposure of cells to HBO and elevated pressure 
For HBO (97.9% O2, 2.1% CO2, 2.4 ATA) and pressure control (2.4 ATA, 8.8% O2, 
2.1% CO2, and 89.1% N2) cells were incubated in stainless steel hyperbaric chambers.  
Chambers were flushed for four minutes with relevant gas mixes and then pressurised to 
2.4 atmosphere absolute (ATA) over two minutes.  To investigate the effect of pressure 
alone cells were incubated at 37 °C in 8.8% O2, 2.1% CO2, and 89.1% N2 at 2.4 ATA.  
8.8% O2 is equivalent to 21% at 1 ATA.  Cultures were exposed to HBO or pressure for 
ninety minutes to replicate the duration of treatment received by hyperbaric therapy 
patients as described in Chapter 2, section 2.10. 
3.2.5 Assessment of osteoclast differentiation  
Osteoclast formation was determined using the specific osteoclastic marker tartrate 
resistant acid phosphatase (TRAP) (Burstone, 1958), as described in Chapter 2, Section 
2.5. 
3.2.6 Assessment of bone resorption 
Slices of bovine cortical bone used as substrates for osteoclastic resorption were 
prepared as previously described (McSheehy and Chambers, 1986) (see Chapter 2, 
Section 2.6). Resorption pits appeared as darkly stained, clearly marginated areas using 
reflected light microscopy and resorption area was quantified across the entire surface 
of the slice using an eye-piece graticule at a magnification of ×40. 
3.2.7 Quantitative RT-PCR 
Quantitative RT-PCR (qPCR) was used to detect gene expression for key regulators of 
osteoclast differentiation using the ∆∆CT methodology.  Details are described in 
Chapter 2, Section 2.9.4. Primer sequences are shown in Table 3.1. 
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Table 3.1 Primer sequences 
Name  Product size 
(base pairs) 
Sequences  
β-actin human 153 F:GCGCGGCTACAGCTTCA  
R:TGGCCGTCAGGCAGCTCGTA 
RANK human 235 F:GGTGGTGTCTGTCAGGGCACG  
R:TCTCCCCCACCTCCAGGGGT 
Dc-STAMP human 166 F:GTTGGCTGCCCTGCACCGAT  
R:TCCCTCATCCTGGGGCTGCC 
NFATc1human 161 F:GGTCTCGAACACTCGCTCTGCC 
R:GCAGTCGGAGACTCGTCCCTGC 
HIF1-α human 295 F:CAGAAATGGCCTTGT  
R:CAGGCTGTGTCGACTGAG 
 
 
3.3 Western blotting  
3.3.1 Preparation of cell lysate 
Total cell lysates were obtained by lysing cells in lysis buffer (0.1% Triton X-100, 20 
mM Tris-chloride, pH 7.9, 1% NP-40, 150 mM NaCl2, 2.5 mM MgCl2 and 5% 
glycerol), with 10× protease inhibitor cocktail (100µl/ml). Cells were grown in six well 
plates, washed with ice cold PBS on ice, scraped from wells and transferred to 1.5 ml 
Eppendorfs. Lysis buffer was added to the cells in the Eppendorfs and then centrifuged 
for five minutes at 8000 ×g. The supernatant was removed and analysed for protein 
content using the BSA assay. This solution was stored at -80 °C until used in western 
blot experiments. 
 60 
 
The Bradford assay and a bovine serum albumin (BSA) standard curve (up to 2 mg/ml) 
were used to quantify the amount of protein in each lysate. 50 µl of each standard or cell 
lysate was mixed with 250 µl of Bradford reagent and the absorbance measured at 595 
nm against a blank composed of 50 µl of water and 250 µl of Bradford reagent. Two 
identical measurements were made for each sample. Absorbance was then plotted 
against BSA concentration and the equation of the line (y = mx +c) used to calculate the 
amount of protein in each sample (Fig. 3.2). The protein concentration of each sample 
was then normalised to controls. Samples were stored at -80 °C until used. 
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Figure 3.2 Calibration graph for protein determination  
 
 
 
 
 
 
 
Y=A (0.214) +B (1.18) x 
R2=0.994 
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3.3.2 SDS-PAGE stand for gel electrophoresis 
10% SDS PAGE gels were prepared for separation of proteins. These were prepared 
with 3.3 ml of 30% acrylamide/bis-acrylamide, 2.5 ml of 1.5 M Tris-chloride, 0.4% 
SDS, pH 8, 4.2 ml of ddH2O and 10% ammonium persulphate (30µl) (APS). TEMED 
(5 µl) was then added to start the crosslinking reaction. Thegel mixture was 
immediately transferred into the cast with a plastic pipette and overlaid with 
isopropanol; to stop oxygen interfering with the polymerisation reaction, then overlaid 
with 150 µl H2O.  
Stacking gels were prepared by mixing 0.67 ml of 30% acrylamide/bis-acrylamide, 1.0 
ml of 0.5 M Tris-chloride, 0.4% SDS, pH 6.8, 10% (30µl) APS and 5 µl of TEMED. 
Liquid was removed from the main gel and the stacking gel poured on top. A plastic 
comb consisting of 15 teeth, matching the thickness of the gel, was then inserted into 
the stacking gel, with care taken not to create any bubbles. The comb was left in the 
stacking gel as it set for 30-40 min. The gel was taken out of the casting equipment and 
put into the gel tank, containing 1× electrophoresis running buffer (12 g Tris base 
(1.3%), 57 g glycine (5.7%), 4 g (3%) SDS in 800 ml, pH 8.3). Cell lysates were 
removed from -80 °C and non-reducing solubilising buffer added to them (0.12 M Tris 
base, 4% (w/v) SDS, 20 %(w/v) glycerol, 0.004% bromophenol blue, pH 6.8). Lysates 
were then heated to 95 °C for 5 min, loaded into wells with 10 µl of biotinylated protein 
ladder and then run for 45-50 min at 200 V. Protein was transferred from SDS-PAGE 
gels onto a polyvinylidene fluoride PVDF membrane prepared for transfer by soaking in 
methanol for 30 s, dH2O for two min and transfer buffer (0.025 M Tris base, 0.192 M 
glycine, 20 % methanol (v/v)) for at least five minutes. Sponges and blotting paper were 
also soaked in cold transfer buffer. Gels were removed from the electrophoresis tank, 
sandwiched in the transfer apparatus and electrophoresis performed at 100 V for 30-40 
min. The membrane was then blocked with blocking buffer (500 ml PBS, 250 µl of 
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0.05% Tween 20, 5% (w/v) milk protein) for 30-60 min with gentle rocking followed 
by three washes of five minutes with (PBS, 0.05% Tween 20). Following this primary 
antibody was diluted according to supplier’s instructions (1:1000) and incubated with 
the membrane overnight at 4 °C. Three washes of five minutes were then made with 5 
ml of (PBS, 0.05% Tween 20) before addition of HRP conjugated secondary antibody 
for 45 min diluted according to supplier’s instructions (1:1000). Finally three washes of 
five minutes were then made with 5 ml of (PBS, 0.05% Tween 20). The blot was then 
developed by incubating with 3 ml of Luminata Crescendo Western HRP substrate 
(Millipore, UK) for five minutes. Membranes were then placed in cling film and bands 
digitally photographed using UVP Bioimaging System.  The optical density of bands 
was then measured using Image J software (NCBI, USA). 
Blots were then stripped in buffer (1.5% glycine, 0.1% w/w SDS, and 1% v/v Tween 20, 
pH 2.2) for one hour and reprobed for GAPDH as described above to check for protein 
levels in lanes. The optical density of the GAPDH band was then measured using Image 
J and these values used to normalise the target band level by calculating relative 
densities.  
3.4 Statistical Analysis 
Statistical analysis was performed using one-way ANOVA for comparison between 
groups.  All results are expressed as mean ± SEM and significance was considered at P 
< 0.05. The analysis was performed using Statview statistical software (Abacus 
Concepts, California, USA). 
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3.5 Results 
3.5.1 HBO, hyperoxia and pressure suppress osteoclast differentiation in RAW 
264.7 cells 
RANKL directly stimulated the formation of TRAP positive osteoclasts within four 
days in normoxic conditions, which similar to previous findings readily formed 
resorption pits on bone slices (Figs 3.3 and 3.4).  Exposure to HBO, pressure or 
hyperoxia for ninety minutes daily significantly reduced the number of TRAP positive 
osteoclasts compare to normoxic conditions, with HBO and pressure having a 
significantly greater effect compared to hyperoxia (Fig. 3.3 A).  Osteoclast formation in 
HBO, hyperoxia and pressure treated cultures was 0.51, 0.75 and 0.50 of normoxic 
control. Osteoclast activity was also significantly reduced to a similar extent by all 
treatments.  The percentage of bone surface displaying resorption pits was 0.36, 0.38 
and 0.44 of control in HBO, hyperoxia and pressure treated cultures, respectively (Fig. 
3.3 B). 
 
 
 
 65 
 
Figure 1
Pe
rc
e
nt
a
ge
 
o
f T
RA
P 
po
si
tiv
e
 
ce
lls
0
5
10
15
20
25
30
35
Normoxia HBO Hyperoxia Pressure
Bo
ne
 
su
rfa
ce
 
re
so
rb
e
d 
(%
)
0.0
0.5
1.0
1.5
2.0
2.5
Normoxia HBO Hyperoxia Pressure
* *
* *
*
*
 
Figure 3.3 Daily exposures to HBO, hyperoxia or pressure inhibited RANKL-induced osteoclast 
formation and bone resorption.  RAW264.7 cells were treated with RANKL (30 ng/ml) and 
incubated in normoxic conditions (21% O2 1 ATA) or normoxic conditions with ninety minutes 
per day (4 days for TRAP, 8 days for resorption) exposure to HBO (97.9% O2 at 2.4 ATA), 
hyperoxia (95% O2, 1ATA) or elevated pressure (8.8% O2, 2.4 ATA). Results are expressed as 
the mean ± SEM of three experiments. (A) Percentage of cultures expressing TRAP positivity, 
(B) percentage of bone surface displaying resorption pits. * P < 0.05 versus normoxia, # P ˂ 
0.05 versus HBO and pressure. 
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Figure 3.4.Images of TRAP stained cultures from normoxia (A-B) and HBO (C-D) treated 
cultures at magnifications of ×100 and ×400.  Image of representative resorption pits taken by 
reflected light microscopy at a magnification of ×200 from a normoxic culture.  Resorption pits 
appear as darkly stained, clearly marginated areas.  
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3.5.2 HBO and hyperoxia suppress osteoclast differentiation in human PBMC 
cultures  
To determine the response of human cells PBMC were exposed to daily HBO, 
hyperoxia and pressure.  HBO and hyperoxia significantly reduced the number of 
RANKL-induced TRAP positive mononuclear and multinuclear osteoclasts formed 
under normoxic conditions (Fig. 3.5).  HBO had a significantly greater inhibitory action 
on osteoclast differentiation than hyperoxia or pressure alone, with pressure increasing 
osteoclast formation compared to the normoxic control.  Mononuclear and multinuclear 
osteoclast formation was 0.16/0.11, 0.39/0.31 and 1.36/2.0 fold changes compared to 
the control in HBO, hyperoxia and pressure treated cultures, respectively. RANKL-
induced bone resorption was significantly decreased by HBO and hyperoxia, with HBO 
having a more pronounced effect than pressure or hyperoxia alone, whereas pressure 
had no significant effect on osteoclast activity.  The extent of bone surface resorbed in 
HBO, hyperoxia and pressure treated cultures was 0.4, 0.5 and 0.65 of the control. 
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Figure 3.5 Daily exposures to HBO and hyperoxic conditions inhibit RANKL-induced 
osteoclast formation and bone resorption.  hPBMC were treated with RANKL (30 ng/ml) and 
M-CSF (30 ng/ml) incubated continuously in normoxic conditions (21% O2, 1 ATA) or 
normoxic conditions with a ninety minute daily exposure to HBO (97.9% O2, 2.4 ATA), 
hyperoxia (95% O2, 1 ATA) or elevated pressure (8.8% O2, 2.4 ATA). Results expressed as the 
mean ± S.E.M. of three experiments. (A) Percentage of TRAP positive mononuclear cells 
within culture (B) percentage of TRAP positive multinuclear cells within culture (C) percentage 
of bone surface displaying resorption pits.  # P < 0.05 versus all groups, * P < 0.05 versus 
normoxia.   
A 
B 
C 
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3.5.3 HBO has a greater effect on osteoclast differentiation than hyperoxia or 
pressure alone in hypoxic conditions 
Osteonecrotic bone tissue is poorly vascularised and as a consequence hypoxic.  
Hypoxia augments osteoclast formation which in turn leads to further osteolysis.  HBO 
is often used as an adjunct to debridement of osteonecrotic bone; with patients receiving 
HBO for ninety minutes per day for 30 days before and ten days after surgery.  
However the effect of HBO on osteoclast formation in hypoxic conditions has not been 
studied, hPBMC were therefor cultured in hypoxic conditions (2% O2) and exposed 
daily (8 days for TRAP and 21 days for resorption) to HBO, hyperoxia or elevated 
pressure for ninety minutes.  
Hypoxia significantly augmented RANKL-induced osteoclast formation in PBMC 
cultures (Fig. 3.6).  Exposure to HBO, hyperoxia or pressure for ninety minutes 
prevented the augmentative action of hypoxia on mononuclear and multinuclear 
osteoclast formation.  However, HBO had a significantly greater effect than hyperoxia 
or pressure alone (Fig. 3.6), with osteoclast number still significantly elevated above 
normoxic conditions in pressure treated cultures. 
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Figure 3.6 HBO has a greater suppressive effect on hypoxia-induced osteoclast formation than 
hyperoxia or pressure alone.  PBMC were treated with RANKL (30 ng/ml) and M-CSF (30 
ng/ml) and incubated continuously in hypoxic conditions (2% O2, 1 ATA) or hypoxic conditions 
with a ninety minute daily exposure to HBO (97.9% oxygen at 2.4 ATA), hyperoxia (95% 
oxygen at 1 ATA) or elevated pressure (8.8% oxygen at 2.4 ATA).  # P < 0.05 versus all other 
groups, * P < 0.05 versus normoxia. 
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3.5.4 HBO suppresses expression of key regulators of osteoclast differentiation in 
hypoxic conditions 
RANKL-induced osteoclast formation is dependent on a complex network of 
intracellular signals that promote expression of genes typical of mature osteoclast.  
RANKL binds to its specific receptor RANK activating downstream signalling 
components that stimulate nuclear translocation of key osteoclastic transcription factors 
such as NFATc1, DC-STAMP and c-fos. Therefore to determine the potential molecular 
mechanism through which HBO suppresses osteoclast differentiation, RANK, DC-
STAMP and NFATc1 mRNA expression were examined using real time quantitative 
PCR.  Hypoxia stimulated a significant 5.57 fold increase in RANK expression in 
developing osteoclasts, which was prevented by daily HBO (Table 3.1).  Hypoxia also 
significantly augmented RANKL-induced DC-STAMP and NFATc1 mRNA expression 
compared to normoxic conditions (Table 3.2) and this was abolished by HBO.  In 
addition, HBO significantly reduced NFATc1 and DC-STAMP expression below those 
measured under normoxic conditions. 
The enhanced rate of osteoclast formation seen in hypoxic conditions has been 
attributed at least in part to changes in HIF expression. Therefore to assess the 
possibility that the anti-osteoclastic effect of HBO was mediated through an action on 
HIF expression, the effect of HBO on HIF-1α mRNA and protein expression was 
examined.  Hypoxia induced a significant 1.33 fold increase in HIF-1α mRNA and 1.5 
fold increase in HIF-1 protein expression (Table 3.3). This increase was abolished by 
daily exposure to HBO, hyperoxia or pressure. The suppressive action of HBO was 
greater than that of hyperoxia which in turn was significantly greater than that of 
pressure alone.  HBO and hyperoxia, but not pressure, significantly decreased HIF 
mRNA expression, and HBO, but not hyperoxia or pressure significantly decreased HIF 
protein levels in comparison to normoxic controls (Table 3.3).  
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Table 3.2 HBO suppresses the stimulatory effect of hypoxia on RANKL-induced NFATc1,  
DC-STAMP and RANK mRNA expression. 
 NFATc1 DC-STAMP RANK 
Normoxia 1  1 1 
Hypoxia 197.7 ± 63.7 # 19.3 ± 9.7 # 5.57 ± 1.7 # 
HBO 0.77 ± 0.15 # 0.53 ± 0.16 # 1.10 ± 0.4 
Values are expressed as RQ relative to normoxic conditions using ∆∆CT, all group’s expression 
are normalised to β-actin.  Values are the means ± S.E.M. of three experiments.  # P < 0.05 
versus all other groups. 
  
 73 
 
Table 3.3 Hypoxia elevates whereas HBO suppresses HIF-1α mRNA and protein expression. 
 
 HIF-1α mRNA HIF-1α protein 
Normoxia 1 1 
Hypoxia 1.33 ± 0.01 # 1.50 ± 0.33 # 
HBO 0.14 ± 0.04 # * 0.59 ± 0.10 # * 
Hyperoxia 0.35 ± 0.08 # * 0.75 ± 0.12 * 
Pressure 0.76 ± 0.28 * 0.88 ± 0.13 * 
 
 
 
 
 
Values are expressed as RQ relative to normoxic conditions using ∆∆CT, all group’s expression 
are normalised to β-actin. Protein expression values are expressed relative to the optical density 
of normoxia bands, all group’s values normalised to GAPDH expression. Values are the means 
± S.E.M. of three experiments. # P < 0.05 versus normoxia. * P<0.05 versus hypoxia. 
 
HIF1-α 
GAPDH 
21%    2%    95%   Pres     HBO 
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3.6 Discussion 
The work in this chapter investigated the effect of HBO, pressure and hyperoxia on 
RANKL-induced osteoclastogenesis.  The major outcomes suggest that daily exposure 
to HBO for ninety minutes significantly suppresses osteoclast differentiation and bone 
resorption in mouse and human monocytes compared to normoxic and hypoxic 
conditions in vitro.  Furthermore, HBO had a greater effect on human osteoclast 
formation than either hyperoxia or elevated pressure alone.  The exposure regime used 
in these experiments replicated that typically administered to patients undergoing 
hyperbaric therapy who receive a course of daily exposures at 2-3 ATM for ninety 
minutes per session.  HBO is employed as an adjuvant therapy in several conditions 
including refractory osteomyelitis and ORN or BRONJ (Ahmed et al., 2009, Vescovi 
and Nammour, 2010, Peleg and Lopez, 2006).  HBO has been shown to improve bone 
graft and dental implant incorporation (Sirin et al., 2011) and is also used to promote 
healing of complicated fractures with mixed outcome (Bennett et al., 2005).  Previous 
studies examining the effect of HBO have primarily focused on changes in osteoblast 
activity.  Data from these investigations indicate that HBO has a positive effect on 
osteoblast differentiation; promoting ALP expression, bone nodule formation and 
mineralisation in vitro.  HBO has also been shown to enhance bone accruement during 
experimental tooth movement (Gokce et al., 2008) and accelerates the healing rate in 
rabbit and rat models of calvarial and mandibular bone regeneration in vivo (Jan et al., 
2006, Muhonen et al., 2004). However, only Gray and Hamblen studies have examined 
the effect of HBO on resorption noting a decrease in 45Ca release from calvarial organ 
cultures (Gray and Hamblen, 1976).  Due to the heterogeneous nature of organ culture it 
is unclear if this represents a direct effect of HBO on monocyte differentiation or an 
indirect action mediated through osteoblast or stromal derived regulators of osteoclast 
formation.  Data from the current studies using RAW264.7 cells, which lack stroma or 
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osteoblasts, suggest that monocytes themselves are directly sensitive to HBO, although 
this does not preclude additional osteoblast-mediated actions in mixed cell populations. 
While the effect of HBO on osteoclastogenesis has until now been poorly documented 
the importance of oxygen in osteoclast differentiation is more widely appreciated.  The 
partial pressure of oxygen in healthy bone is similar to that measured in other tissues (6-
9%), however in diseased or necrotic bone much lower partial pressures of 0.5 to 4% 
have been recorded (Maurer et al., 2006).  Osteoclast differentiation and activity is 
acutely sensitive to changes in tissue oxygen levels. Hypoxia enhances osteoclast 
differentiation through a direct effect on monocytic precursors (Zhao et al., 2011, 
Srinivasan and Avadhani, 2007) and indirectly by promoting the release of cytokines 
such as VEGF, IGF and IL-6 that support osteoclast formation (Arnett et al., 2003, 
Fukuoka et al., 2005, Knowles and Athanasou, 2008, Utting et al., 2010).  Hypoxia has 
also been shown to reduce levels of IL-10, an inhibitor of osteoclast differentiation 
(Naldini et al., 1997).  Prolonged hypoxia also augmented osteoclast formation in the 
current studies and this was prevented by daily HBO exposure. This is in keeping with 
the studies of Muzylak and Arnett (Arnett et al., 2003, Muzylak et al., 2006) but 
contrasts somewhat with Knowles and Leger where exposure to hypoxic conditions for 
longer than twenty four hours or continuous HIF-1α expression was associated with a 
loss of membrane integrity and reduced osteoclast number (Knowles and Athanasou, 
2009, Leger et al., 2010). The reason for this discrepancy is unclear but may relate to 
differences in culture methods employed.  The current experimental cultures and those 
of Arnett and Muzylak et al (2003) required daily re-gassing, during which short 
periods of higher O2 partial pressures may have occurred, whereas Knowles and Leger’s 
cultures were maintained at a constant 2% O2.  Knowles and Leger showed that 
exposing cells to normoxic conditions for one hour per day prevented the anti-
osteoclastic effect of hypoxia.  However, the physiological relevance of a suppressive 
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effect of 2% O2 is uncertain as increased osteoclast formation and resorption are noted 
in ischemic models of necrosis (Bejar et al., 2005, Kim et al., 2006) and bone resorption 
is a characteristic of metastatic breast tumours in spite of the low partial pressure within 
and adjacent to tumours (Hiraga et al., 2007). Furthermore, oxygen levels fluctuate 
during ischemic injury due to the initiation of angiogenesis and other reparative 
mechanisms and it is therefore possible that transient changes in oxygen partial pressure 
represent a more realistic model.  Whatever the answer, it is clear from the current 
studies that HBO suppressed RANKL-induced osteoclast formation and bone resorption 
in cells that were otherwise maintained in normoxic and hypoxic conditions. 
While HBO consistently suppressed osteoclast formation, human and murine precursors 
displayed a differential response to pressure under normoxic conditions. Similar to 
Rubin’s studies using mouse marrow cultures (Rubin et al., 1997) elevated pressure had 
an anti-osteoclastic effect on RAW264.7 cells but augmented RANKL-induced 
osteoclast formation in human PBMC.  This may reflect a species difference or could 
have arisen due to an in-direct action of pressure on a small numbers of lymphocytes 
present within PBMC cultures.  HBO has been shown to induce lymphocyte apoptosis 
and reduce TNF-α production in human blood cells whereas elevated pressure alone has 
no effect (Chen et al., 2007, Benson et al., 2003), and as TNF-α augments RANKL-
induced osteoclast formation the continued presence of TNF-α producing lymphocytes 
within pressure treated cultures would be expected to provide a greater stimulus for 
osteoclast differentiation than in HBO treated cultures. Furthermore, despite the 
increase in osteoclast number in human cultures there was no corresponding increase in 
pit formation suggesting that pressure may inhibit mature osteoclast resorptive activity. 
The anti-osteoclastic effect of HBO was more pronounced than either hyperoxia or 
elevated pressure alone indicating that appropriate combinations of pressure and 
hyperoxia are the most effective therapeutic strategy. To assess the molecular 
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mechanism mediating the anti-osteoclastic effect of HBO this study examined 
expression of key mediators of RANKL-induced osteoclast differentiation. RANKL 
binds to its membrane bound receptor RANK on monocytic precursors, which, via 
TRAF 2, 3 and 6, activates downstream transcription factors that control expression of 
genes typical of osteoclasts such as TRAP and DC-STAMP. Pivotal to this is the c-fos 
and Ca2+ dependent activation of NFATc1 (Matsuo et al., 2004).  RANK or NFATc1 
deficient mice lack osteoclasts and are severely osteopetrotic as a consequence and it is 
suggested that NFATc1 alone may be sufficient to induce osteoclast formation under 
appropriate conditions (Matsuo et al., 2004).  Culturing PBMC in hypoxic conditions 
significantly elevated RANK expression in the presence of RANKL and this may in part 
mediate the augmentative effect of hypoxia on osteoclast differentiation.  This is in 
keeping with the recent studies of Tang which suggest that hypoxia-induced RANK 
expression in MDA-MB-231 breast cancer cells contributes to the osteolysis associated 
with breast metastases (Tang et al., 2011).  Furthermore, SNPs in RANK are associated 
with an increased risk of developing BRONJ (Katz et al., 2011), suggesting a central 
role for aberrant RANK signalling in ischaemic bone loss.  HBO may at least in part 
reduce osteoclast formation in compared to hypoxic conditions by preventing the 
elevation in RANK expression.  However, HBO also suppressed osteoclast formation in 
compared to normoxic conditions when RANK was not elevated, suggesting that this is 
not the only mechanism by which HBO acts.  It is likely that suppression of NFATc1 
expression or activity also contributes to the anti-osteoclastic action.  This assertion is 
strengthened by the significant decrease in NFATc1 and NFAT dependent fusion 
protein DC-STAMP mRNA expression in HBO treated cultures. The mechanism 
through which HBO suppresses NFATc1 expression may relate to an effect on upstream 
control elements such as NF-κB or c-fos.  However, it is unlikely that c-fos represents 
the primary target for HBO as the c-fos promoter lacks oxygen responsive elements and 
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HBO has been shown to have contrasting effects on c-fos expression, decreasing LPS-
induced expression in the brain stems of rats (Lin and Wan, 2008) and increasing 
expression in endothelial cells (Godman et al., 2010).  In contrast the NF-κB promoter 
contains oxygen responsive elements and its expression and activity are acutely 
sensitive to changes in oxygen, with hypoxia elevating and HBO suppressing NF-κB 
levels and activity (Walmsley et al., 2005, Yu et al., 2009). 
The ability of osteoclasts to sense changes in oxygen level is dependent on the HIF 
pathway which regulates the cellular response to hypoxia in many tissues.  Under 
normoxic conditions HIF proteins are rapidly degraded following hydroxylation of 
conserved proline residues by PHD.  These hydroxylated residues are targeted by the 
ubiquitin ligase VHL.  In ischaemic tissues PHD activity is suppressed allowing the 
accumulation of HIF heterodimers that drive expression of oxygen sensitive genes such 
as NF-κB.  Hypoxia increases osteoclast HIF-1α activity leading to the expression of 
hypoxic responsive genes such as VEGF (Knowles and Athanasou, 2008); osteoclasts 
lacking HIF-1α do not respond to changes in oxygen partial pressure (Knowles and 
Athanasou, 2008, Zhao et al., 2011) whereas inducers of HIF-1α stimulate resorption 
(Knowles et al., 2010).  Hypoxia increased HIF-1α expression in human PBMC in our 
studies, which was reversed by HBO with HIF-1α mRNA and protein expression falling 
markedly below that in normoxic controls.  Hyperoxia also reversed the effect of 
hypoxia; however it did not reduce HIF protein levels below that of normoxic 
conditions.  In contrast, HIF mRNA and protein levels were not drastically affected by 
pressure which corresponds to pressure’s modest effect on osteoclast differentiation.  
This suggests that at least in part the anti-osteoclastic action of HBO may be mediated 
through a reduction in HIF-1α, which would be expected to decrease expression of 
hypoxic responsive genes such as NF-κB and thereby limit NFATc1 expression and 
osteoclast formation. 
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HBO has a direct suppressive effect on osteoclast differentiation and activity in 
normoxic and hypoxic conditions.  Thus, the beneficial effect of adjunctive HBO on 
necrotic bone may occur in part due to a reduction in aberrant osteoclast activity.  This 
provides evidence supporting the use of HBO as an adjunctive therapy to prevent 
osteoclast formation in a range of skeletal disorders associated with low oxygen partial 
pressure. 
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Chapter four: Hyperbaric oxygen therapy suppresses the 
osteoclast forming ability of peripheral blood monocytes: an 
ex-vivo study 
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4.1 Introduction 
HBO increases the partial pressure of oxygen dissolved in plasma and tissues, which 
reduces hypoxia and stimulates angiogenesis in hypovascular tissue (Grim et al., 1990).  
This can help in a number of pathologies where tissues have experienced decreased 
oxygen levels (Cohn, 1986). For instance in oral and maxillofacial surgery HBO is often 
used to treat osteoradionecrosis (ORN;Vudiniabola et al., 1999). Osteonecrosis is a 
complication of radiotherapy or high dose bisphosphonate therapy employed in the 
treatment of a range of secondary bone cancers. Irradiation decreases hard and soft 
tissue vascularity leading to hypoxia which then in turn promotes bone necrosis, and 
dysfunctional macrophage and fibroblast activity during wound healing (Marx, 1983). 
HBO is often used in these patients prior to reconstructive surgery to repair damaged 
skeletal elements. A single HBO session for ORN commonly consists of the patient 
breathing 100% oxygen at 2-2.4 ATA for 90-120 min; usually treatment occurs on a 
daily basis, five to six days per week until the required number of sessions is completed 
(Vudiniabola et al., 1999). HBO is considered a valuable adjunct for the healing of bone 
lesions in different anatomical regions with ischemic perfusion and also has uses in the 
treatment of osteomyelitis and the potential to augment bone turnover (Broussard, 2004, 
Freiberger, 2009)
  
Following on from the previous chapter in which in vitro application of HBO inhibited 
RANKL induced osteoclast formation and bone resorption in cell lines and human 
PBMC, the effect of HBO on osteoclast formation was further examined by establishing 
the effect of in vivo HBO on osteoclast formation and bone resorption ex vivo.  Blood 
was obtained from consenting individuals undergoing HBO at the DDRC and the ability 
of their monocytic precursors to form bone resorptive osteoclasts prior to and following 
HBO therapy was assessed. The effect of HBO on the intracellular mechanisms that 
regulate osteoclast formation was also examined. 
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4.2 Expermintal setup 
 
 
Figure 4.1 Experimental design. Six patients from DDRC were enrolled in this study. Patients 
were exposed to HBO treatment (1 session per day) according to a routine therapy protocol in 
the multiplace chamber. Blood samples were taken from each after repeated exposure to HBO 
(pre HBO, 10 and 25 HBO treatments). 
 83 
 
4.2.1 Ethical Considerations and sample preparation 
 
All studies reported in this chapter were approved by Plymouth and Cornwall NHS 
Ethics Committee and all subjects provided written informed consent. Blood samples 
were taken from consenting patients referred for HBO by their consultants to the 
Plymouth Hyperbaric Medical Centre (Diving Disease Research Centre, DDRC). 
Patients, who were over 18 and had English as first language, were considered for 
inclusion. Patients were given a minimum of 24 h to consider participation before being 
consented by the DDRC research nurse. Subjects who were considered by the clinical 
team to be too frail or unwell to have blood taken were not invited to participate in the 
study. 
The clinical history of consenting individuals was ascertained by the research nurse at 
the DDRC. Six male patients were recruited with an age range of (49-83 years); three 
were receiving HBO for chronic wound healing and the other three for radiation tissue 
damage (Table 4.1).  Patients were exposed to HBO inside a multiplace chamber.  
Patients were provided with a sealed breathing mask from which they received 100 % 
O2 at 2.4 ATA for 90 min daily, including air breaks for 5 min to minimise the risk of 
oxygen toxicity.  The first blood sample was taken on the same day as the first HBO 
session one hour before treatment.  Subsequent samples were taken before the patient 
had their eleventh (10 treatment group) and twenty sixth treatment (25 treatment group), 
about 21 h after HBO the previous day. Patients were asked to donate a total of 60 ml 
blood collected in Vacutainers via venepuncture by the research nurse/doctor at the 
DDRC. Blood was collected into potassium EDTA Vacutainer tubes to prevent clotting 
and kept at room temperature until cell cultures were set up after 2 h.  
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Table 4.1 Patient information  
 
Patient Number Age at Time of Treatment Sex Reason for HBO 
1 63 Male Problem Wound 
(diabetic – type 1) 
2 70 Male Radiation Tissue 
Damage 
(not diabetic) 
3 66 Male Radiation Tissue 
Damage 
(not diabetic) 
4 49 Male Problem Wound 
(diabetic – type 2) 
5 49 Male Radiation Tissue 
Damage 
(not diabetic) 
6 83 Male Problem Wound 
(diabetic – type 2) 
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Figure 4.2 Representation of a multiplace chamber with patients undergoing HBO at DDRC 
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4.2.2 Isolation and culture of peripheral blood monocytes 
Peripheral blood was obtained from healthy volunteers by venipuncture, using heparin 
to prevent coagulation in accordance with approved ethical guidelines. The blood was 
collected by a research nurse at the DDRC. Blood was diluted 1:1 in un-supplemented 
media (α-MEM). Mononuclear cells were isolated by centrifuging 15 ml of α-MEM 
blood suspension over 25 ml of Histopaque-1077 (Sigma-Aldrich, UK), as described in 
Chapter 2, Section 2.4 (Fig 4.1). 
4.2.3 Assessment of osteoclast differentiation  
Osteoclast formation was determined using the specific osteoclastic marker tartrate 
resistant acid phosphatase (TRAP), as described in Chapter 2, Section 2.5. The number 
of TRAP-positive and negative cells was recorded at five predetermined sites in each 
well using a light microscope fitted with an eye-piece graticule (Olympus, Japan) at 40× 
magnification.  The percentage of TRAP positive cells was recorded for each well and a 
mean ± S.E.M. was calculated for the group.  
4.2.4 Assessment of bone resorption 
Slices of bovine cortical bone used as substrates for osteoclastic resorption were 
prepared as previously described Chapter 2, Section 2.6.  After appropriate incubation 
times cells were removed from the surface of the bone slice by immersion in sodium 
hypochlorite for five minutes, washed in distilled water for five minutes and staining 
with 1% toluidine blue solution for ten minutes.  Slices were then air-dried and mounted 
on glass slides.  Resorption pits appeared as darkly stained, clearly marginated areas 
using reflected light microscopy and resorption area was quantified across the entire 
surface of the slice using an eye-piece graticule at a magnification of ×40. 
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4.2.5 Quantitative RT-PCR 
Quantitative RT-PCR (qPCR) was used to detect gene expression for key regulators of 
osteoclast differentiation using the ∆∆CT methodology, as described in Chapter 2. The 
forward and reverse primer sets used for PCR are shown in Table 4.2. 
Table 4.2 Primer sequences 
Name  Product size  Sequences  
Human β-actin 153 F:GCGCGGCTACAGCTTCA  
R:TGGCCGTCAGGCAGCTCGTA 
Human RANK 235 F:GGTGGTGTCTGTCAGGGCACG  
R:TCTCCCCCACCTCCAGGGGT 
Human Dc-STAMP 166 F:GTTGGCTGCCCTGCACCGAT  
R:TCCCTCATCCTGGGGCTGCC 
Human NFATc1 161 F:GGTCTCGAACACTCGCTCTGCC 
R:GCAGTCGGAGACTCGTCCCTGC 
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4.3 Statistical Analysis 
Statistical analysis was performed using one way ANOVA for comparison between 
groups.  All results are expressed as mean ± S.E.M. and significance was considered at 
P < 0.05. The analysis was performed using Stat view statistical software (Abacus 
Concepts, California, USA). 
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4.4 Results 
4.4.1 The effect of HBO on osteoclast formation and bone resorption  
HBO suppressed the ability of PBMC to form RANKL-induced osteoclasts. Daily HBO 
treatment significantly reduced RANKL-induced TRAP positive mononuclear cell 
formation in a treatment number-dependent manner (Figs 4.3 and 4.4).  RANKL 
induced a significant five-fold increase in the number of mononuclear osteoclast 
compared to M-CSF controls. Ten HBO sessions for ninety minutes per day 
significantly reduced the number of RANKL-induced TRAP positive osteoclasts that 
formed, causing a 50% decrease in mononuclear osteoclast number compared with pre 
HBO, although osteoclast number did not return to control levels.  TRAP positive 
mononuclear osteoclast formation was, however, suppressed to control levels after 25 
HBO sessions which caused an 80% decrease compared with pre HBO number (Figs 
4.3 and 4.4). 
Similar suppressive effects of HBO were noted on multinuclear osteoclast formation.  
Once more, RANKL induced a significant increase in osteoclast number compared with 
the pre HBO treatment group.  However, in contrast to the effect on mononuclear cells 
10 HBO sessions had no significant suppressive effect on RANKL-induced 
multinuclear osteoclast formation whereas 25 sessions significantly suppressed 
multinuclear osteoclast formation again returning numbers to control levels (Figs 4.4 
and 4.5). 
When the effects of HBO on mononuclear and multinuclear cells were assessed together, 
RANKL induced a significant 5 fold increase in TRAP positive osteoclast number. Ten 
HBO treatments significantly suppressed the number of TRAP positive cells (60% of 
pre-HBO), but did not decrease numbers to control levels. Osteoclast formation 
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following 25 HBO treatments was not significantly different from control and was 
significantly less than pre-HBO (20% of pre-HBO) and 10 treatments (Figs 4.4 and 4.6). 
Next, this study investigated the ability of hPBMC to form resorption pits on slices of 
bovine cortical bone. As expected in the RANKL treated pre HBO group osteoclast 
produced characteristic resorption pits after 21 days, which was decreased in a 
treatment-dependent manner by HBO (Fig. 4.8 B-D).  Similar to its effect on 
mononuclear osteoclast 10 HBO treatments significantly reduced bone resorption area 
to 20% of the area of pre-HBO cultures.  Resorption was further reduced after 25 
treatments being 10% of pre HBO values and not significantly different from M-CSF 
controls (Figs 4.7 and 4.8). 
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Figure 4.3 HBO (100% O2, 2.4 ATA) supressed RANKL-induced mononucleated osteoclast 
formation, hPBMC were obtained from patients undergoing HBO therapy and treated with 
RANKL (30 ng/ml) and M-CSF (30 ng/ml) for 12 days. Data are expressed as mean ± S.E.M., n 
= 6. ** P ˂ 0.05 compared to control, * P ˂ 0.05 compared to pre HBO, # P ˂ 0.05 compared to 
10 treatments. 
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Figure 4.4 The effect of HBO (100% O2, 2.4 ATA) treatment on hPBMC treated with RANKL 
(30 ng/ml) and M-CSF (30 ng/ml) on TRAP staining on day 12 of culture (magnification ×40). 
Samples were obtained from patients undergoing HBO at the DDRC. Digital images taken from 
inverted microscope (A) M-CSF control (B) osteoclast formation pre HBO (C) osteoclast 
formation after 10 HBO treatments (D) osteoclast formation after 25 HBO treatments. TRAP 
positive mononuclear (Mo) and multinuclear (Mu) cells by arrowheads. 
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Figure 4.5 HBO (100% O2, 2.4 ATA) supressed RANKL-induced multinucleated osteoclast 
formation. hPBMC were obtained from patients undergoing HBO at the DDRC and treated with 
RANKL (30 ng/ml) and M-CSF (30 ng/ml) for 12 days before staining for TRAP. Data are 
expressed as mean ± S.E.M., n = 6. ** P ˂ 0.05 compared to control, * P ˂ 0.05 compared to pre 
HBO, # P ˂ 0.05 compared to 10 treatments. 
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Figure 4.6 HBO (100% O2, 2.4 ATA) supressed RANKL-induced osteoclast formation in 
hPBMC obtained from patients undergoing HBO at the DDRC. hPBMC were treated with 
RANKL (30 ng/ml) and M-CSF (30 ng/ml) for 12 days, and then stained for TRAP. Data are 
expressed as mean ± S.E.M., n = 6. ** P ˂ 0.05 compared to control, * P ˂ 0.05 compared to pre 
HBO, # P ˂ 0.05 compared to 10 times treatment. 
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Figure 4.7 Daily exposure to HBO inhibits RANKL-induced bone resorption.  hPBMC obtained 
from patients undergoing HBO therapy at the DDRC were treated with RANKL (30 ng/ml) and 
M-CSF (30 ng/ml) for 21 days before resorption was assessed. Results expressed as the mean ± 
S.E.M., n = 6. # p < 0.05 versus pre HBO treatment, ** p < 0.05 versus control, * p < 0.05 
versus 10 treatment.  
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Figure 4.8 Images of resorption pits taken by reflected light microscopy.  Resorption pits appear 
as darkly stained, clearly marginated areas. Resorption was quantified across the entire surface 
of the slice using an eyepiece graticule at a magnification of ×40. (A) M-SCF control (B) pre 
HBO (C) 10 treatments (D) 25 treatments. Arrows point to pits.  
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4.4.2 Effect of HBO on osteoclastic gene expression  
The effect of HBO on RANK, DC-STAMP and NFATc1 mRNA expression was 
examined. RANK mRNA was significantly increased by 10 HBO treatments with a 3.5 
fold increase compared with pre HBO treatment group. However there was a significant 
decrease in RANK expression after 25 treatments, which was 50% of pre-HBO levels 
(Fig. 4.9). The expression profile of DC-STAMP also displayed a similar change in 
expression.  DC-STAMP expression significantly increased after 10 HBO treatments 
with a 2.3 fold increase compare with pre HBO treatment group. This again was 
followed by a significant decrease in expression after 25 HBO treatments (Fig. 4.10).  In 
contrast HBO had a less pronounced effect on NFATc1 expression 10 treatments 
significantly reduced NFATc1 expression by 30% compared with pre HBO, but no 
significant effect was noted after 25 treatments (Fig. 4.11). 
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Figure 4.9 Effect of HBO on RANK mRNA expression. Monocytes were isolated from patients 
before and after HBO, cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) and mRNA 
extracted after 14 days. cDNA was synthesised from extracted RNA and qPCR used to 
determine RANK expression. Gene expression was normalised against an endogenous control 
(β-actin). Data expressed as the mean ± S.E.M., n = 6. # P ˂ 0.05 versus 10 treatments, *p ˂ 0.05 
versus pre HBO. 
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Figure 4.10 Effect of HBO on DC-STAMP mRNA expression. Monocytes were isolated from 
patients before and after HBO, cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) and 
mRNA extracted after 14 days culture. cDNA was synthesised from extracted RNA and qPCR 
used to determine DC-STAMP expression. Gene expression was normalised against an 
endogenous control (β-actin). Data expressed as the mean ± S.E.M., n=6. # P ˂ 0.05 versus 10 
treatment, * p ˂ 0.05 versus pre HBO. 
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Figure 4.11 Effect of HBO on NFATc1 expression. Monocytes were isolated from patients 
before and after HBO cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) and mRNA 
extracted after 14 days. cDNA was synthesised from extracted RNA and qPCR used to 
determine NFATc1 expression.  Gene expression was normalised against an endogenous control 
(β-actin). Data expressed as the mean ± S.E.M., n = 6. 
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4.5 Discussion 
The previous chapter suggests that HBO has a direct inhibitory effect on osteoclast 
differentiation and bone resorption.  In the current study hPBMC of patients undergoing 
HBO were used to study the effect of HBO on the ability of precursors to respond to 
RANKL ex vivo. The outcomes from this study confirm the results from the previous 
chapter as HBO suppressed the ability of peripheral blood monocytes to develop into 
RANKL-induced resorptive osteoclast.  As this is an ex-vivo culture system this 
suggests that the suppressive effect was meditated by an action of HBO prior to 
RANKL activation in vitro and must therefore be mediated via an inhibitory effect on 
the ability of precursors to differentiate along the osteoclastic lineage. This may reflect a 
direct action on the precursors themselves or alternatively an indirect action mediated 
through stromal cells that support precursor development.  The effect of HBO would 
also appear to be accumulative with a greater effect noted with further treatments.  
There was also an initial differential response of multinuclear and mononuclear cells to 
HBO. While HBO suppressed mononuclear osteoclast formation within ten treatments, 
multinuclear osteoclast formation was not suppressed by this exposure number.  The 
apparent resistance of multinuclear osteoclasts may reflect an accumulative effect of 
HBO on mononuclear cell formation.  Multinuclear cells form by the fusion of 
mononuclear cells and it is likely that the number of mononuclear cells able to 
differentiate into osteoclasts falls as the number of exposures increases.  Therefore 
during the earlier stages of treatment there will be precursors present that would be able 
to differentiate into mononuclear osteoclasts and fuse to form multinuclear osteoclasts.  
This assertion is supported by the lack of a significant reduction in DC-STAMP 
expression, which facilitates membrane fusion, at ten treatments. DC-STAMP would 
support fusion and therefore maintain multinuclear osteoclast number. The subsequent 
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fall in DC-STAMP expression correlates with a decrease in multinuclear number 
providing further weight to this. 
In addition, the inhibitory effect of HBO could be due to changes in the distribution of 
mononuclear cells (Bitterman et al., 1993). The monocyte-macrophage is an important 
source of IL-1 and IL-6, HBO has generally been shown to suppress inflammation by 
reducing inflammatory and increasing anti-inflammatory cytokine production (Brenner 
et al., 1999). For instance in patients with Crohn’s disease treated with 100% O2 for 90 
min at 2.4 ATA, LPS-stimulated monocyte-macrophages secreted less IL-1, IL-6 and 
TNF-α than cells obtained prior to treatment (Weisz et al., 1997). Benson et al found 
that HBO attenuates inflammatory cytokine production in vivo in animal models of 
systemic inflammation and they found that HBO exposure transiently supresses 
stimulus-induced proinflammatory cytokine production (Benson et al., 2003).  Jimi et al 
indicated that IL-1 induces the multinucleation and bone-resorbing activity of 
osteoclasts even in the absence of osteoblast/stromal cells (Jimi et al., 1999) and IL-1 is 
a potent stimulator of bone resorption in vivo (Boyce et al., 1989). Also TNF-α 
stimulates osteoclastogenesis in vitro and in vivo directly stimulating osteoclast 
formation from human or mouse monocytes (Kudo et al., 2002) and augmenting 
RANKL-induced osteoclastogenesis (Fox  et al., 2008). Other studies have shown that 
HBO increases IL-10 production by stimulated splenic T cells suggesting that HBO 
treatment has a broad effect on the adaptive immune response (Kudchadkar et al., 2008). 
IL-10 is an important suppressor of bone resorption in vivo, and it appears that the anti-
osteoclastic mechanisms induced by IL-10 are more effective than those mediated by 
IL-4 (Sasaki et al., 2000). Hong et al found that the inhibitory effect of IL-10 on OC 
formation is mediated on OC precursor cells and this inhibitory effect may be useful in 
a wide variety of osteoporotic disease (Hong et al., 2000). Fox and Evans also 
demonstrated that IL-10 acts directly on mononuclear precursors and indicated that IL-
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10 directly inhibits osteoclastogenesis by suppressing NFATc1 activity (Evans and Fox, 
2007). 
Whatever the mechanism it is clear that one way HBO induces resistance to RANKL-
induced osteoclast formation is by modifying RANK expression.  In Chapter 3 it was 
shown that HBO significantly reduces RANK expression. Similarly in the current 
studies 25 HBO sessions caused a significant decrease in RANK expression.  HBO may 
therefore at least in part reduce osteoclast formation by preventing the elevation in 
RANK expression. However the in-vivo response to HBO is not as straight forward as 
that noted in vitro as 10 exposures increased RANK expression.  This suggests that in 
vivo the response of monocytic cells may depend on their differentiation stage, with 
newly formed or immature precursors displaying a decrease in RANK whereas more 
mature precursors respond with an increased expression. This concept is again 
supported by changes in multinuclear osteoclast formation and DC-STAMP expression, 
with 10 exposures increasing whereas 25 exposures suppressing expression and 
multinuclear osteoclast number. As DC-STAMP is a marker of late stage osteoclast 
formation, and enables fusion of mononuclear cells, this suggests that in vivo HBO in 
the short term may potentially accelerate the development of osteoclasts by facilitating 
the response to RANKL. 
This data shows that NFATc1 expression was little effected by repeated HBO treatment 
in contrast to the previous chapter. This may reflect the nature of the treatment sessions. 
The implications of this data for patient treatment regimens also needs further 
clarification as it is unclear if the suppressive effect would be present if only 10 sessions 
were administered or if the further 15 sessions are needed for this to occur.  This is of 
clinical importance as shorter but equally effective treatment regime would greatly 
reduce the financial cost and issues with patient compliance.  
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Previous studies demonstrated that osteonecrosis is a common complication of radio or 
high dose bisphosphonate therapy for secondary bone cancer. HBO is often used in 
these patients prior to reconstructive surgery to repair damaged skeletal elements and it 
also used in the management of other skeletal disorders.  Evidence for its effectiveness 
comes from a range of sources. Chen et al concluded that HBO is effective and safe for 
chronic refractory osteomyelitis provided that patients had received appropriate medical 
and surgical management (Chen et al., 2003). HBO has been used in the treatment of 
stage I avascular necrosis of the head of the femur (Ries et al., 2002). Granstrom 
recommended the uses of HBO as an adjunctive treatment in the rehabilitation of oral 
cancer patients (Granstrom, 2003). Freiberger et al demonstrated that adjunctive HBO 
may benefit patients with BRONJ (Freiberger, 2009). In 1983 Marx demonstrated that 
HBO and aggressive surgery in a progressively staged manner was able to achieve 
complete resolution of ORN (Marx, 1983). However, HBO is widely employed the 
cellular and molecular mechanism of its action is poorly understood. Previous work 
addressing this issue has shown that both resorptive osteoclasts and formative 
osteoblasts respond to changes in oxygen concentration.   
These findings suggest that HBO suppresses osteoclast formation and bone resorption 
from circulating monocytes.  This would appear to be due to an action on early stages of 
precursor development and is associated with appropriate changes in the expression of 
osteoclastic genes. This study advances our knowledge of the effect of HBO on 
osteoclast formation, and hence adds to knowledge and understanding of the mechanistic 
action of this therapy in the treatment of osteonecrotic bone loss.  
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Chapter five: The effect of hyperbaric oxygen therapy on 
osteoblast differentiation and bone formation in vitro 
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5.1 Introduction  
Bone homeostasis depends on appropriate osteoblast and osteoclast activity. Aberrant 
remodelling underpins bone loss in several debilitating skeletal diseases such as 
osteoporosis, metastatic breast cancer and multiple myeloma. Hyperbaric oxygen is 
used as an adjunctive therapy in the treatment of osteoradionecrosis and chronic 
osteomyelitis of the jaw after radiotherapy or in cases of BRONJ. HBO has been used to 
promote healing of irradiated mandibular bone since 1973 (Mainous and Hart, 1975) 
and is also used to promote bone healing (Bennett et al., 2005). For instance HBO has 
been used in patients with bone grafts (Kerwin et al., 2000) dental implants (Granstrom 
et al., 1999) and destruction osteogenesis (Clark et al., 2006). 
Several studies have shown a positive effect of HBO on bone healing and bone 
formation (Penttinen et al., 1972, Nilsson et al., 1988, Nilsson, 1989, Jan et al., 2010). 
Jan et al (2009) demonstrated that the hypoxic state that commonly follows bone and 
blood vessel injury inhibits fibroblast proliferation, collagen synthesis and granulation 
tissue formation (Jan et al., 2009). Penttinen et al (1972) found that HBO produced a 
state of intermittent hyperoxia which alternated with periods of hypoxia maintaining the 
stimulus for healing at least in part through an ability to promote angiogenesis.  Further 
evidence for this is provided by studies using rabbit irradiated mandible bone harvest 
chambers in which HBO stimulates ALP activity and angiogenesis (Muhonen et al., 
2004).  Therefore through an effect on capillary proliferation HBO may help restore 
osteoblast formation at formally hypoxic sites.  It is clear also that oxygen partial 
pressure directly impacts on osteoblast function as hypoxic conditions similar to those 
associated with anaemia, diabetes and arthritis decrease formation and nodule 
mineralization in cultured osteoblast in vitro (Utting et al., 2006).  In addition it is 
possible that HBO may also have direct actions on osteoblasts that further enhance its 
regenerative capacity; however this has not been extensively examined. Therefore to 
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determine the direct effect of HBO on osteoblast differentiation and bone nodule 
formation, this study examined the effect of HBO, pressure and hyperoxia on 
proliferation, expression of key regulators and markers of osteoblast differentiation, and 
mineralised nodule formation compared to normoxic and hypoxic conditions.  
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5.2 Experimental design 
 
 
 
Figure 5.1 Experimental design. Saos-2 cells were differentiated using differentiation agents and 
were exposed to different oxygen treatments. 
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5.2.1 Cell culture 
Saos-2 human osteoblast-like cells were obtained from ECACC (Porton Down, UK), 
(ECACC cat. no.8905205) and cultured in Dulbecco’s minimum essential medium 
supplemented with 10% charcoal stripped fetal calf serum (Autogen Bioclear, UK)2 
mmol/l glutamine, 100 IU/ml benzylpenicillin and 100 mg/ml streptomycin all from 
Sigma (Poole, Dorset, UK). All incubations were performed at 37 °C in 5% CO2, and 
cultures were fed every 2-3 days by replacing half the medium with fresh medium. 
For in vitro treatment of cells with HBO (97.9% O2, 2.4 ATA), elevated pressure (2.4 
ATA, 8.8% O2, 2.1% CO2 and 89.1% N2) and hyperoxic conditions (95% O2) cells were 
incubated in air-tight stainless steel chambers prepared at the DDRC.  Chambers were 
flushed for four minutes with relevant gas mixes and then pressurised to 2.4 atmosphere 
absolute (ATA) over two minutes as described in Chapter 2, Sections 2.10 and 2.11. 
Cultures were exposed to HBO or pressure for ninety minutes to replicate the duration 
of treatment received by hyperbaric therapy patients. 
For hypoxia (2% O2), normoxia (21% O2) and hyperoxia (95% O2) treatments cells 
were incubated in special air tight chambers prepared at the DDRC in a total volume of 
five litres. Chambers were flushed with appropriate gas mixtures
 
for ninety minutes and 
then sealed. Chambers were re-gassed daily as above with appropriate O2 
concentrations. 
5.2.2 Measurement of proliferation  
This assay was measured by using using the Cell Titer 96 AQeous non-radioactive cell 
proliferation kit, as described in Chapter 2, Section 2.7. 
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5.2.3 Measurement of mineralization 
Saos-2 human osteoblast-like cells were cultured in 96 well plates (5 × 104 per well) and 
treated with β-GB (10 mM) and L-AA (50 mg/l), and then mineralization was assessed 
using a modification of Hale’s methodology (Hale et al., 2000) by measuring calcein 
incorporation, as described in Chapter 2, Section 2.8. 
5.2.4 Alkaline phosphatase activity (ALP) 
Saos-2 human osteoblast-like cells were cultured and treated as described above in 
Section 5.2.3. ALP activity was measured by staining cultures with p-nitrophenyl 
phosphate (1 mg/ml) at 37 °C for 30 min. Absorbance was measured at 405 nm and the 
results normalized to total cell number. 
5.2.5 Real time quantitative PCR analysis 
Saos-2 cells (1 × 10 6 cells per well) were incubated in six well plates for four or seven 
days while receiving relevant experimental treatments. Total RNA was then isolated and 
quantified on a Nanodrop spectrophotometer, cDNA was synthesised from RNA 
isolates using the ImPromII Reverse Transcription System (Promega, Southampton, 
UK).  Real time PCR was performed on a StepOne PCR system (Applied 
Biosystems,UK) using the DNA-binding dye SYBR green for detection of PCR product 
as described in Chapter 2, Section 2.9.4.  The forward and reverse primer sets used for 
PCR were as follows (Table 5.1). 
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Table 5.1 Primer sequences of osteoblastic transcriptional factors 
Target sequence  Product size 
(base pairs)  
Sequences  
β-actin 153 F:GCGCGGCTACAGCTTCA  
R:TGGCCGTCAGGCAGCTCGTA 
Runx-2 157 F:AGACCCCAGGCAGGCACAGT 
R:GCGCCTAGGCACATCGGTGA 
type I collagen 153 F:CCTGGCAGCCCTGGTCCTGA 
R:CTTGCCGGGCTCTCCAGCAG 
 
 
5.3 Statistical analysis  
Differences between groups were assessed using Fisher’s one way analysis of variance 
(Statview; Abacus Concepts, USA). A difference of P < 0.05 was considered 
statistically significant. 
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5.4 Results 
5.4.1 HBO augments early stages of mineralization 
The effect of HBO on mineralization was assessed in cultures of Saos-2 cells incubated 
in the presence of differentiation agents (L-AA and β-GP). All treatment groups were 
significantly different from the control group (no β-GP 10 mM or L-AA) at all time 
points examined. Compared to normoxic conditions, HBO significantly enhanced 
mineralization at seven days inducing a 1.55 fold increase in comparison with the 
normoxia group. At 14 days HBO induced a significant 1.4 fold increase in 
mineralization in comparison to normoxia. In contrast, at 21 days HBO had no 
significant effect when compared to time matched normoxic groups (Figs 5.1 and 5.2).  
At 7 days hyperoxia induced a significant 1.3 fold decrease in mineralization compared 
with normoxia and at 14 and 21 days had no significant effect on calcein incorporation. 
Pressure alone had no significant effect on mineralization at 7, 14 or 21 days compared 
with normoxia (Figs 5.2 5.3). 
To replicate the hypoxic environment associated with necrotic bone, experiments were 
then performed in hypoxic conditions. Hypoxia inhibits growth and differentiation of 
osteoblasts as shown from the literature (Utting et al., 2006) and at 14 and 21 days 
hypoxia caused a significant 1.9 and 1.2 fold reduction in mineralization. Similar to the 
effect of HBO on calcein incorporation in normoxic conditions, HBO had a pronounced 
augmentative effect on mineralization reversing the suppressive hypoxic action at all 
time points. At 7 days HBO induced a significant 1.3 fold increase in mineralization 
compared with normoxia and 1.5 fold compared with hypoxia. At 14 days HBO had the 
greatest effect compared to the other treatments and significantly increased 
mineralization 1.4 fold versus normoxia and 2.7 fold versus hypoxia. At 21 days HBO 
also significantly enhanced mineralization inducing a 1.5 fold increase compared with 
normoxia and 1.8 fold increase compared with hypoxia (Figs 5.2 and 5.4).  
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At seven days hyperoxia significantly enhanced osteoblastic mineralization with a 1.2 
fold increase compared to cultures continuously grown in normoxic conditions and a 1.4 
fold increase compared to cell cultures exposed to intermittent hypoxic conditions. At 
14 days hyperoxia reversed the suppressive effect of hypoxia, but did not increase 
mineralisation beyond that of normoxic control.  Hyperoxia at 21 days induced a 
significant 1.2 and 1.5 fold increase in comparison with normoxia and hypoxia groups 
(Figs 5.2 and 5.4).  
At 7 days pressure stimulated a significant 1.2 and 1.3 fold increase in calcein 
incorporation compared with normoxia and hypoxia, respectively. At 14 days pressure 
reversed the suppressive effect of hypoxia but did not enhance mineralization beyond 
that of normoxic control with a 1.2 fold increase in comparison with hypoxia treatment 
group. In contrast at 21 days pressure significantly enhanced mineralisation with 1.2 
and 1.5 fold increases compared to normoxic and hypoxic cultures (Figs 5.2 and 5.4). 
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Figure 5.2 Bone nodule formation Saos-2 cells cultured for 7, 14 and 21 days in the presence of 
differentiation agents (β-GP and L-AA), pictures taken from inverted microscope  (A) control 
(no β-GP or L-AA) (B) normoxia (C) hypoxia (D) hyperoxia (E) pressure (F) HBO. Arrows 
highlight mineralised nodules. 
  
7 Days 
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Figure 5.3 HBO enhances early stages of mineralization in normoxic conditions. Saos-2 cells 
were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 50 mg/l) for 7, 14 and 21 days and 
exposed to various treatments daily for 90 minutes. Mineralization was then assessed using a 
calcein incorporation assay. Values are mean of three replicates with their standard errors 
represented by vertical bars.  Differences between groups were assessed by one-way ANOVA. * 
Significantly different from all groups (P < 0.05). ** Significantly different from normoxic 
group (P < 0.05). 
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Figure 5.4 The effect of HBO, pressure and hyperoxia on osteoblast activity in hypoxic 
conditions. Saos-2 cells were treated with β-GP (10 mM) and L-AA, (50 mg/l) for 7, 14 or 21 
days. Values are expressed as the mean of three replicates with standard errors represented by 
vertical bars.  Differences between groups were assessed by one-way ANOVA. * Significantly 
different from normoxia group (P < 0.05). #Significantly different from hypoxic group (P < 
0.05). 
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5.4.2 HBO promotes osteoblast proliferation in normoxic and hypoxic conditions  
The effect of treatment on cell number was assessed at days 4, 7 and 14. Under 
normoxic conditions HBO increased cell number with an 8.7 fold increase at four days, 
1.1 fold increases at seven days and a 9.6 fold increase at 14 days (Fig. 5.5). 
In contrast, hyperoxia only had a positive effect on cell number at four days inducing a 
7.7 fold increase in number compared to normoxia.  At seven days hyperoxia reduced 
cell number causing a 1.4 fold decrease compared with normoxia. At 14 days hyperoxia 
had no significant effect on cell number compared to normoxia (Fig. 5.5).  
Pressure alone induced a 2.7 fold increase in cell number at four days, had no 
significant effect at seven days and significantly enhanced osteoblast proliferation at 
fourteen days with a 2.3 fold increase compared to normoxia (Fig. 5.5).  
Hypoxia caused a significant 1.6 and 7.7 fold decrease in osteoblastic proliferation at 
four and seven days. But no significant effect was noted at 14 days. HBO had no 
significant effect on cell number at four days compared to normoxia and hypoxia 
groups; at seven days HBO reversed the suppressive effect of hypoxia but did not 
augment cell number beyond that of normoxic control. At 14 days HBO had the greatest 
effect on osteoblast proliferation in hypoxic conditions inducing a 9.6 fold increase 
compared with normoxia and 1.9 fold increase compared with hypoxia. 
At 4 days hyperoxia reversed the suppressive effect of hypoxia but did not augment cell 
number beyond that of normoxic control with 1.6 fold increase compared to hypoxic 
group. At 7 days hyperoxia was unable to prevent the suppressive effect of hypoxia.  
Similarly at 14 days hyperoxia had no significant difference compared to normoxia or 
hypoxia groups. 
At 4 days pressure had no effect on cell number. However, it reversed the suppressive 
action of hypoxia at seven days, augmenting cell number beyond that of normoxic 
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control with a 2.8 fold increase compared to hypoxia group. Pressure at 14 days had no 
effect compared with normoxia and hypoxia treatment groups (Fig. 5.6). 
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Figure 5.5 The effect of HBO, pressure and hyperoxia on osteoblast number in normoxic 
conditions. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 50 mg/l) 
and cell number assessed using an MTS assay at 4, 7, and 14 days Values are the mean of three 
replicates with their standard errors represented by vertical bars.  Differences between groups 
were assessed by one-way ANOVA. *Mean values of group were significantly different from 
normoxic control (P < 0.05). 
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Figure 5.6 The effect of HBO, pressure, and hyperoxia on osteoblast number in hypoxic 
conditions. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 50 mg/l) 
and cell number assessed using an MTS assay at 4, 7 and 14 days. Values are mean of three 
replicates with their standard errors represented by vertical bars. Differences between groups 
were assessed by one-way ANOVA. * Significantly different from the normoxia control               
(p< 0.05). # Significantly different from hypoxia treatment groups (P < 0.05). 
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5.4.3 HBO treatment stimulates ALP activity  
Unsurprisingly ALP activity, a marker for osteoblast differentiation, increased in the 
presence of the known promoters of osteoblast differentiation β-GP and L-AA as the 
cultures progressed. Under normoxic conditions ALP activity was significantly 
enhanced in HBO-treated cultures at four and seven days which induced a 1.8 and 1.2 
fold increase, respectively, whereas HBO had no significant effect on ALP activity at 14 
days. At 4 days hyperoxia had no significant effect on ALP activity compared with 
normoxia; at seven days hyperoxia reduced ALP activity significantly with 1.2 fold 
decrease compared to normoxia. This suppression was not seen at fourteen days and 
ALP activity was not different from normoxia. Pressure significantly increased ALP 
activity at four days compared with normoxic group inducing a 1.8 fold increase.  
Unexpectedly pressure decreased ALP activity at 7 days and again this suppressive 
action was not seen at fourteen days (Fig. 5.7).  
 At 4 days hypoxia induced a modest increase in ALP activity compared to normoxia. 
At seven days hypoxia significantly decreased ALP activity with a 1.8 fold reduction 
compared to normoxia.  While ALP activity was suppressed at day 14 compared with 
normoxia this did not reach statistical significance (Fig. 5.8). 
At 4 days HBO significantly elevated ALP activity in comparison with other groups 
with a 1.7 fold increase compare with normoxia. At 7 days HBO reversed the 
suppressive effect of hypoxia but did not augment ALP activity beyond that of 
normoxic control, inducing a 1.5 fold increase compared to hypoxia group. At 14 days 
HBO significantly stimulated ALP activity compared to normoxia (1.2 fold) and 
hypoxia (1.3 fold) treated cultures (Fig. 5.8). At four days hyperoxia had no significant 
effect on ALP activity.  At 7 days hyperoxia was unable to prevent the suppressive 
effect of hypoxia. However at fourteen days hyperoxia significantly enhanced ALP 
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activity with 1.2 and 1.3 fold increases compared to normoxia and hypoxia respectively 
(Fig. 5.8). 
Pressure enhanced ALP activity in comparison to normoxia at four days but was not as 
strongly as hypoxia or HBO.  At 7 days pressure partly reversed the suppressive effect 
of hypoxia but did not restore ALP to normoxic levels (Fig. 5.7).  At 14 days daily 
exposure for ninety minutes to pressure significantly stimulated ALP activity inducing a 
1.3 and 1.4 fold increase compared to normoxia and hypoxia treated cultures 
respectively (Fig. 5.8). 
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Figure 5.7 The effect of HBO, pressure, and hyperoxia on ALP activity in normoxic conditions. 
Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 50 mg/l) and ALP 
activity assayed after 4, 7 and 14 days. Values are mean of three replicates with their standard 
errors represented by vertical bars.  Differences between groups were assessed by one-way 
ANOVA. * Significantly different from normoxia (P < 0.05).  
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Figure 5.8 The effect of HBO, pressure, and hyperoxia on osteoblast activity in hypoxic 
conditions, ALP activity assay for 4, 7, and 14 days. Saos-2 cells were treated with β-GP (10 
mM) and L-ascorbic acid (L-AA, 50 mg/l) and ALP activity assayed after 4, 7 and 14 days. 
Values are mean of three replicates with their standard errors represented by vertical bars.  
Differences between groups were assessed by one-way ANOVA. * Significantly different from 
normoxia group (P < 0.05).  # Significantly different from hypoxia (P < 0.05). 
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5.4.4 HBO enhances Runx-2 and type I collagen expression  
Osteoblast differentiation is regulated by transcription factors that control gene 
expression. Therefore to determine the potential molecular mechanism by which HBO 
enhances early stages of osteoblast differentiation Runx-2 expression was examined 
using real time quantitative PCR. HBO significantly increased Runx-2 expression 
stimulating a 7.1 fold increase compared to normoxia. Hyperoxia also significantly 
enhanced Runx2 expression stimulating a 2.7 fold increase compared with normoxia. In 
contrast pressure had no significant effect on Runx-2 expression (Fig. 5.9).  Hypoxia 
significantly reduced mRNA expression of Runx-2 with a 2.8 fold decrease compared to 
normoxia.  Daily exposure to HBO for ninety minutes significantly increased Runx-2 
expression inducing an 8.3 fold increase compared with normoxia and 22.6 fold 
increase compared with hypoxia.  Hyperoxia and pressure had no significant effect on 
Runx-2 expression compared to normoxia and hypoxia groups (Fig. 5.10). 
Type I collagen is highly expressed in osteoblast and is the most abundant protein of 
bone extracellular matrix. Type I collagen is expressed in osteoblast at all stages during 
development (Kern et al., 2001).  In normoxic conditions HBO had a great effect on 
type I collagen expression compared to other treatment groups, stimulating a 4.5 fold 
increase compared to normoxia.  In contrast hyperoxia and pressure had no effect on 
type I collagen expression (Fig. 5.11).  Interestingly hypoxia significantly decreased 
type I collagen expression; hypoxia reduced a 1.4 fold decrease compared with 
normoxia, whereas HBO significantly enhanced type I collagen mRNA expression; 
HBO induced a 1.6 fold increase compared with normoxia and 2.4 fold increase 
compared with hypoxia. In contrast hyperoxia significantly reduced type I collagen 
mRNA expression compared with normoxia and hypoxia, and pressure was unable to 
reverse the suppressive effect of hypoxia (Fig. 5.12). 
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Figure 5.9 The effect of HBO, pressure and hyperoxia on Runx-2 expression, in normoxic 
conditions for 7 days. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 
50 mg/l). Quantification of this mRNA expression normalized against β-actin mRNA level. 
Values are mean of three replicates with their standard errors represented by vertical bars.  
Differences between groups were assessed by one-way ANOVA. * Significantly different from 
normoxia (P < 0.05). 
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Figure 5.10 The effect of HBO, pressure and hyperoxia on Runx-2 expression in hypoxic 
conditions for 7 days. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic acid (L-AA, 
50 mg/l). Quantification of this mRNA expression normalized against β-actin mRNA level. 
Values are mean of three replicates with their standard errors represented by vertical bars.  
Differences between groups were assessed by one-way ANOVA. * Significantly different from 
normoxia group (P < 0.05). # Significantly different from hypoxia group (P < 0.05). 
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Figure 5.11 The effect of HBO, pressure and hyperoxia on type I collagen expression in 
normoxic conditions for 7 days. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic 
acid (L-AA, 50 mg/l). Quantification of this mRNA expression normalized against β-actin 
mRNA level. Values are means of three replicates with their standard errors represented by 
vertical bars.  Differences between groups were assessed by one-way ANOVA. * Significantly 
different from normoxia (P < 0.05).  
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Figure 5.12 The effect of HBO, pressure and hyperoxia on type I collagen expression, in 
hypoxic conditions for 7 days. Saos-2 cells were treated with β-GP (10 mM) and L-ascorbic 
acid (L-AA, 50 mg/l).  Quantification of this mRNA expression normalized against β-actin 
mRNA level. Values are mean of three replicates with their standard errors represented by 
vertical bars.  Differences between groups were assessed by one-way ANOVA.  * Significantly 
different from normoxia groups (P < 0.05). # Significantly different from hypoxia groups (P < 
0.05). 
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5.5 Discussion 
Appropriate bone remodelling is dependent on a delicate balance between osteoblastic 
bone formation and osteoclastic resorption. Disruption of the balance between these cell 
types is often seen in bone diseases such as osteoporosis, metastatic breast cancer, 
multiple myeloma and osteomyelitis (Duplomb et al., 2007).  Changes in remodelling 
activity can also arise as a consequence of therapeutic intervention for instance 
intravenous bisphosphonate treatment is associated with BRONJ and localised ORN is a 
common side effect of radiotherapy (Migliorati et al., 2006).  
In the current study Saos-2 cells were used to study the effects of HBO, pressure and 
hyperoxia in normoxic and hypoxic conditions.  The results indicate that intermittent 
HBO exposure, similar to that received by patients with osteonecrosis of the jaw or 
complicated fractures, augments early stages of bone nodule formation in normoxic 
conditions. Furthermore, HBO had a greater effect on bone nodule formation than either 
hyperoxia or pressure alone. This beneficial action was also noted in hypoxia and the 
effect appeared to be extended beyond that seen in normoxic conditions, indicating that 
HBO is able to reverse the suppressive action of hypoxia at later stages of osteoblast 
differentiation and bone formation.  This is similar to the studies of Wang in which 
HBO promoted osteoblast activity and improved outcomes when applied during the 
early stages of the tibial healing process (Wang et al., 2005).  This augmentative action 
may at least in part be due to an increase in the number of osteoblasts as HBO 
significantly increased osteoblast number in both normoxic and hypoxic conditions and 
HBO had the largest effect in comparison with hyperoxia and pressure alone; this is 
similar to the study of Mainous (1977) which demonstrated that treatment of 
mandibular osteoradionecrosis with HBO increased collagen formation, fibroblast 
proliferation, capillary budding, osteoblastic and osteoclastic activity, callus formation 
and mineralization. This action, however, was not consistent with any effect on 
 131 
 
osteoblast number noted in hypoxic conditions at day four of culture. Similar rapid 
changes in osteoblast number were seen in the studies of Wu et al (2007) which 
demonstrated an initial significant stimulatory effect of HBO treatment within three 
days (Wu et al., 2007).  Ozawa et al (1990) examined the effect of a continuous static 
pressure on the differentiation of osteoblast and found that differentiation was inhibited, 
as were collagen synthesis and alkaline phosphatase activity. Rubin et al. (1997) 
demonstrated that pressure is also known to generate responses from bone cells and 
continuous hydrostatic pressure at physiological levels decreased osteoclast formation 
in marrow cultures. 
The response of osteoblasts to hypoxia has been well documented (Tuncay et al., 1994, 
Steinbrech et al., 2000). Osteoblast function and bone formation are strongly oxygen 
dependent; bone nodule formation was strongly inhibited when oxygen concentration 
was decreased to 5% and almost completely prevented when oxygen concentration was 
1% (Utting et al., 2006). Hypoxia inhibits the proliferation of mature osteoblast 
precursors and leads to the failure of cell differentiation and formation in vitro (Utting et 
al., 2006). Potier et al (2007) suggested that exposure of mesenchymal stromal cell 
(MSCs) transplanted in vivo to hypoxia may affect their bone forming potential (Potier 
et al., 2007). Salim et al (2004) indicated that brief exposure to hypoxia down-regulated 
Runx2 expression, thus inhibiting critical steps in the osteogenic differentiation of 
pluripotent mesenchymal precursors and committed osteoblasts (Salim et al., 2004).  In 
the current studies hypoxia reduced nodule formation at seven and fourteen days which 
was associated with a suppression of osteoblast number, ALP activity and Runx2 
expression. This was consistently reversed by the application of daily HBO, which 
elevated mineralisation, cell number and Runx-2 expression beyond that of normoxic 
controls. In keeping with Utting et al (2006) bone nodule formation was inhibited by 
hypoxia at both early and late stages (Utting et al., 2006). In addition as this cultures 
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lack any other cell types this suggests that HBO has direct actions on osteoblasts to 
promote differentiation and activity in addition to any further angiogeneic effects that 
may occur in vivo. 
There have been in vivo studies on HBO;  Gokce et al (2008) found that HBO enhanced 
bone formation during experimental tooth movement and demonstrated that osteoblastic 
activity might be modulated by changes in oxygen tension (Gokce et al., 2008). 
Muhonen et al (2004) concluded that radiotherapy disturbs distraction bone formation 
and neovascularization, and HBO increased osteoblast activity and angiogenic response 
in rabbit mandibular distraction (Muhonen et al., 2004). Some authors suggested that 
the proliferative effects of hyperbaric oxygen therapy on osteoblasts may contribute to 
the recruitment of osteoblasts at fracture sites and could promote the proliferation of 
growth-arrested osteoblasts (Hsieh et al., 2010). Elevated oxygen conditions induced 
mesenchymal tissue differentiation toward osteoblasts (Warren et al., 2001). Also this 
data shows that HBO elevated ALP activity at all time points in normoxic conditions 
and a similar action was noted in hypoxic conditions at 4 and 14 days similar to the 
studies of Okubo et al (2011) who found that alkaline phosphatase activity and calcium 
content were significantly greater with HBO at day 7 and 21 (Okubo et al., 2001).  
Further studies demonstrated the role of oxygen in bone remodelling by the direct effect 
on collagen synthesis, ALP activity, and the production of transcriptional regulators of 
osteoblast differentiation and bone formation (Warren et al., 2001). 
To assess the molecular mechanisms, this study examined the effect of HBO on key 
markers of osteoblast differentiation Runx-2 and type I collagen. Type I collagen is the 
major organic component of bone matrix and is a marker of mature osteoblasts (Lynch 
et al., 1995).  This study showed that HBO enhances Runx-2 expression at seven days 
which coincides with a significant increase in nodule formation in normoxic and 
hypoxic conditions. Ontiveros et al (2004) demonstrated that hypoxia decreased Runx-2 
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in osteoblast grown in standard tissue culture plates and it also noted this in my studies 
(Ontiveros et al., 2004). Hypoxia also has been shown to decrease alkaline phosphatase 
activity in primary fetal rat calvarial osteoblast cultures exposed to hypoxia as was 
noted at day 7 in these experiments (Tuncay et al., 1994). They also suggested that 
modulation of oxygen concentration could differentially regulate bone cell phenotypes 
and thereby stimulate skeletal homeostasis. This data also shows that HBO appears to 
promote the expression of the major component of bone matrix type I collagen a marker 
of early mature osteoblast in both normoxic and hypoxic conditions. HBO had a greater 
effect on these key markers of osteoblast differentiation than hyperoxia or pressure 
alone, which is in keeping with Ishii’s studies that suggest that intermittent HBO 
enhances collagen synthesis and is beneficial for producing extracellular matrices in 
tissue engineering (Ishii et al., 1999).  
HBO has been used as an adjunctive therapy in many of these disorders with varying 
outcomes.  Several studies demonstrate that oxygen concentration influences bone 
remodelling, and HBO has a positive effect on osteoblast activity (Warren et al., 2001, 
Wu et al., 2007).  Previous studies (Sawai et al., 1996) undertaken to evaluate the effect 
of hyperbaric oxygen therapy on autogenous free bone grafts transplanted from iliac 
crest to the mandibles of rabbits indicate that HBO accelerates the rate of union.  
Similarly the effect of HBO treatment on the healing of normally regenerate bone 
injuries has been extensively investigated using different experimental settings. In 
earlier studies adjunctive HBO was found to amend calcium binding and opposition of 
femur fracture (Coulson et al., 1966). In animal studies HBO has been shown to 
improve both bone generation and the removal of dead or abnormal bone (Tkachenko et 
al., 1988). Ueng et al suggested that the bone healing of tibia is enhanced by 
intermittent HBO (Ueng et al., 1998). Previous studies demonstrated that HBO 
decreased tissue damage and induced osteodentine formation in the rat mandible after 
 134 
 
vertical osteotomy (Nilson et al., 1987). Mainous (1977) treated mandibular 
osteoradionecrosis with HBO and concluded that when the partial pressure of oxygen 
increased, collagen formation and fibroblastic proliferation, capillary budding, 
osteoblastic and osteoclastic activity, callus formation and mineralization were all 
increased (Mainous, 1977). Wray and Rogers 1968 supported the healing of standard 
tibial fracture in rats treated with hyperbaric oxygen for six hours per day at 2 ATA for 
20 to 26 days post-fracture revealed that although callus formation was increased the 
breaking strength was reduced as compared to atmospheric controls (Wray and Rogers, 
1968). Sirin et al assessed the potential effect of HBO on artificial bone grafts in rat 
tibiae and they suggested that HBO had beneficial effects on the healing of unfilled 
bone defects and those filled with β-tricalcium phosphate (Sirin et al., 2011). Thus, the 
general consensus from the limited in vivo studies is that HBO typically has a beneficial 
effect on osteoblast activity. 
Although the potential mechanisms underlying the changes in gene expression with 
HBO remain unclear, previous studies report that HBO applied during the early stage of 
tibial healing was more effective than at later stages in terms of increasing bone mineral 
density and mechanical properties (Wang et al., 2005). This is in keeping with the data 
obtained here, which showed that in normoxic conditions HBO enhanced the early 
stages of osteoblast differentiation. These findings suggest that HBO accelerates the rate 
of osteoblast differentiation and augments early stages of mineralization, and has a more 
pronounced effect than hyperoxia or pressure alone.  This supports the use of HBO as 
an adjunctive therapy to prevent bone loss in a range of skeletal disorders associated 
with low oxygen partial pressure, and also provides a potential mechanism through 
which short term HBO therapy may help in fracture healing. 
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Chapter six: General discussion 
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6.1 Discussion 
Bone remodelling requires the coordinated regulation of osteoblast and osteoclast 
activity (Nair et al., 1996). Remodelling is disrupted in many skeletal diseases including 
osteoradionecrosis and osteomyelitis. Hyperbaric oxygen therapy may support 
remodelling at these sites (Freiberger, 2009). This current study however shows that 
HBO can regulate bone cell activity by several mechanisms; it can directly suppress 
osteoclast differentiation and activity in normoxic and hypoxic conditions and 
accelerate the rate of osteoblast differentiation and mineralization. In Chapter 3 the 
results show that HBO for ninety minutes suppressed osteoclast differentiation and bone 
resorption from mouse and human monocytes in normoxic and hypoxic conditions in 
vitro. Furthermore, HBO had a greater effect on osteoclast formation than either 
hyperoxia or elevated pressure alone in both culture systems, indicating that appropriate 
combinations of pressure and hyperoxia are the most effective therapeutic strategy. 
HBO suppressed RANKL-induced osteoclast differentiation at least in part by 
decreasing RANK, NFATc1 and DC-STAMP expression. The suppressive effect of 
HBO on NFATc1 expression may relate to an effect on upstream control elements such 
as NF-κB or c-fos.  HBO also inhibited HIF-1α gene and protein expression in the 
presence of RANKL.  This suggests that the anti-osteoclastic action of HBO may be 
mediated through a reduction in HIF-1α, which would be expected to decrease 
expression of hypoxic responsive genes such as NF-κB and thereby limit NFATc1 
expression and osteoclast formation. HIF-1α is stabilized by NADPH oxidase during 
hypoxia (Goyal et al., 2004). Therefore, suppression of NADPH oxidase by HBO 
(Ostrowski et al., 2006) may mediate redox-dependent HIF-1α degradation; also the 
accumulation of HIF-1α in ischaemic or hypoxic tissues might promote adaptive 
mechanisms for cell survival (Goyal et al., 2004). The mechanisms by which HIF 
moderate osteoclast functional longevity remain poorly understood and are an area for 
future study. 
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HBO also inhibits the ability of precursors to form osteoclasts, HBO is often used in 
patients prior to reconstructive surgery to repair damaged skeletal elements and it is also 
used effectively in the management of other skeletal disorders. This study therefore 
examined the effect of HBO on the ability of precursors to subsequently respond to 
RANKL ex vivo. HBO suppressed the ability of peripheral blood monocytes to develop 
into RANKL-induced resorptive osteoclasts.  HBO only caused a significant decrease in 
RANK and DC-STAMP expression after 10 treatment sessions so the response of 
monocytes may depend on their differentiation stage, with newly formed or immature 
precursors displaying an increase in RANK whereas more mature precursors responding 
with decreased expression.  This concept is again supported by changes in multinuclear 
osteoclast formation and DC-STAMP expression. This indicates that as the suppressive 
effect was meditated by HBO prior to activation of osteoclast differentiation this may be 
mediated via an inhibitory effect on precursor lineage switching. 
In addition to the direct effect of HBO on osteoclast formation HBO in my studies also 
had direct effects on osteoblasts. The results in Chapter 5 indicate that HBO accelerates 
the rate of osteoblast differentiation and augments early stages of mineralization, and 
has a more pronounced effect than hyperoxia or pressure alone. HBO enhances Runx-2 
mRNA expression and also causes a significant increase in bone nodule formation in 
normoxic and hypoxic conditions. It also promotes expression of the major component 
of bone matrix type I collagen a marker of early mature osteoblast in both normoxic and 
hypoxic conditions. HBO had a greater effect on these markers of osteoblast 
differentiation than hyperoxia or pressure alone. This also provides a potential 
mechanism through which short term HBO therapy may help in fracture healing. In 
keeping with this, several studies have proved the efficacy of HBO therapy in 
improving bone healing or bone formation. Penttinen et al (1972) found in their study 
that intermittent exposure of rats to HBO resulted in hypertrophy of the cartilage and an 
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increase in the rate of bone formation, also in animal studies showed that HBO can be 
used to treat delayed fracture healing (Ueng et al., 1998, Bennett et al., 2005). 
Previous work evaluating the effect of HBO on injured or irradiated sites showed 
increased bone apposition or decreased osteoclastic activity (Gokce et al., 2008). For 
instance Jan et al concluded that HBO stimulated bone formation in defects grafted with 
demineralized bone matrix and resulted in a large reduction in fibrous tissue and an 
increase in its replacement with marrow (Jan et al., 2010).  In animal studies HBO 
improved bone generation (Inoue et al., 2000, Tkachenko et al., 1988) and assisted the 
removal of necrotic bone (Jones et al., 1991, Strauss  et al., 1982). The benefits of HBO 
were less clear in a more recent study where cats with experimentally induced non-
union bone showed increased bone formation but not improved vascularisation (Kerwin 
et al., 2000). There have been reports of clinical improvement following the application 
of HBO to individuals with established non-union (Atesalp et al., 2002). Enrico et al 
(2010) demonstrated an effective treatment modality that involves the use of HBO to 
treat patients with femoral head necrosis (Enrico et al., 2010). An increase in oxygen 
tension within regenerating tissue could promote collagen and adenosine-triphosphate 
(ATP) synthesis (Ishii et al., 1999) leading to changes in osteoblastic and osteoclastic 
activity (Nilsson et al., 1988). The potential mechanisms by which HBO effects bone 
remodelling have not been fully determined. 
In conclusion this study provides evidence that HBO has direct beneficial effects on 
osteoblast and osteoclast activity in addition to further potential angiogenic effects in 
vivo.  Suppression of osteoclastic resorption and promotion of bone formation would be 
expected to increase bone tissue mass and help provide a more suitable site for 
reconstructive surgery or potentially enhance fracture repair rate. The studies add to the 
knowledge and understanding of the potential mechanistic action of this therapy in the 
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treatment of osteonecrotic bone loss and complicated fracture and also indicate that 
HBO may promote the formation of new tissue for dental implants. 
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6.2 Future work 
While this work adds to the field further investigations are still needed to examine the 
effect of HBO on serum biochemical markers of remodelling such as n-mid OCN. 
Serum OCN is widely used as a marker of bone formation and studies have shown that 
OCN levels correlate well with direct invasive measures of bone formation (Takahashi 
et al., 2000). Similarly the effect of HBO on resorption markers, such as c-terminal 
telopeptides of type-I collagen (CTx) would also be useful (Bonde et al., 1995).  This 
would enable the assessment of HBO on remodelling activity in vivo, which was not 
possible in the present study due to the requirement of overnight fasting and the frailty 
of the study cohort. 
The impact of HBO on the levels of TNF-R, IL-1R, c-fos, NFkB, p38, TREM2, DAP12, 
and OSCAR has not been studied in human subjects and would further enhance 
understanding of the mechanism of action.  In addition the effect of HBO on the oxygen 
sensing mechanism in monocytes and differentiating osteoclasts has also not been 
established, so it is better to measure the level of oxygen sensing proteins pVHL, HIF-
2α, and PHD1-3. The effect of HBO on HIF-1α may be better investigated by other 
technique, for instance electromobility shift assay (EMSA). This would reveal the 
extent of HIF-1-binding to DNA indicating not just the amount of HIF-1α formed 
following HBO treatment but also the degree of activity (Kim et al., 2006 ). To further 
elucidate the role of HIF-1α in osteoclast and osteoblast function HIF-1α levels could be 
knocked down with small interfering RNA (siRNA) and the response of osteoclast and 
osteoblast in hypoxic conditions examined (Knowles & Athanasou, 2009).   
The minimum number of treatments to see beneficial effects on bone cell function is 
also unclear.  The results of the current study suggest that this lies somewhere between 
10 and 30 treatments. However, whether 10 treatments are sufficient or more are 
required cannot be ascertained from the current time points.  Therefore in order to 
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establish the effect of accumulative treatments a more in depth study of HBO treatments 
with samples taken after each session between 10 and 30 treatments needs to be 
conducted.  Bone cell activity at these times would then be compared to time matched 
controls that had only received 10 sessions. 
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